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ABSTRACT
Chemical probes are important tools in examining biological mechanisms and potential
therapeutics. Along the direction of studying sulfur signaling, perthiol species (RSnH, n≥2) and
hydrogen polysulfides (H2Sn, n≥2) play essential roles in various physiological and pathological
pathways and have promising therapeutic potentials such as vasodilation, anti-inflammation, and
anti-oxidation effect.

They can directly influence protein activity by post-translational

modification. One of the major bottlenecks in researching the roles of perthiol species and
hydrogen persulfide is the lack of proper prodrugs as both research tools and therapeutic
reagents. Herein, we have developed a series of enzyme-sensitive prodrugs of perthiol species
and hydrogen polysulfides with a controllable release mechanism and kinetics. The utility of
these prodrugs has been validated in various biological models.
Life-threatening infections caused by multi-drug resistant (MDR) bacteria pose a great
threat to public health. The emergence of MDR bacteria at an increasing rate coincides with a
decrease in new antibiotics development. Therefore, there is an urgent need for the discovery of

new antimicrobials to counter this looming health problem. Along this line, we have developed
compounds that sensitize Gram-negative strains towards a wide range of existing antibiotics,
including those that are otherwise narrow-spectrum and not effective against Gram-negative
bacteria. These compounds work by disrupting the outer membrane of Gram-negative bacteria.
Very importantly, such sensitizers exhibited a much lower propensity to induce resistance in
bacteria than commonly used antibiotics.

INDEX WORDS: Hydrogen sulfide prodrug, perthiol species prodrug, hydrogen persulfide
prodrug, antibiotics development, bacterial sensitizer
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1

DEVELOPMENT OF NOVEL PRODRUGS OF PERTHIOL SPECIES AND
HYDROGEN PERSULFIDE

1.1

Introduction
1.1.1

The essential role of hydrogen sulfide

H2S is a volatile gas with pKa values being 6.88 and 19 for the first and second
dissociation steps at 37°C. Thus, under physiological conditions, H2S mainly exists in the neutral
(H2S) and the monoionized (HS−) forms.1 H2S has strong reducing power and nucleophilicity,
which are the basic chemical properties that contribute to their roles in various physiological
pathways.2 H2S has high affinity to iron-containing molecules such as heme and binds directly to
the ferric heme α3 center. Such binding completely inhibits cytochrome c oxidase activity,
leading to inhibition of the mitochondrial respiration and subsequent toxicity at high
concentrations.2 This is also the major reason for its notorious reputation as a poisonous gas.
Recent studies show that hydrogen sulfide (H2S) plays essential roles in physiological
and pathological processes and has promising therapeutic potential on par with that of nitric
oxide (NO) and carbon monoxide (CO).2-6 H2S has been recognized as the third gasotransmitter
with various activities such as anti-inflammation,7-9 ion channel regulation,10-11 cardiovascular
protection,12-15 and antioxidation effects.16-17 H2S is known to be a physiologic vasorelaxant.
Deletion of cystathionine γ-lyase (CSE), a major H2S producing enzyme would lead to decreased
H2S concentrations in serum and consequently hypertension in mice.13 H2S can also induce
suspended animation in mice by inhibiting oxygen consumption and metabolic rates.6, 18-19
H2S can be produced endogenously by three enzymes: cystathionine β-synthase (CBS),
cystathionine γ-lyase (CSE), and 3-mercaptopyruvate sulfurtransferase (3MST) as part of
cysteine metabolism.3, 20-21 The metabolism of H2S happens in the mitochondria via a sulfide

2

oxidation pathway, during which H2S is oxidized all the way to sulfate through persulfide and
sulfite intermediate.22-26 H2S concentration in blood is in a range of high nanomolar to low
micromolar.4, 27

1.1.2

Challenges in developing H2S donors

The significant roles H2S plays in the biological pathways highlight the need for the
development of H2S donors for research and therapeutic purposes. Challenges in developing H2S
donors first come from the bell-shaped toxicity profile with a narrow therapeutic window, which
means the delivery of H2S is needs to be well controlled.4, 27 Secondly, because of the volatility
and quick metabolism of H2S, a bolus administration of H2S would only lead to a spike of H2S
concentration (possible to a dangerous concentration) followed by quick clearance. In reality, a
sustained and constant level of H2S for certain duration would be far more desirable than a quick
spike for therapeutic applications. H2S prodrugs need to be stable enough for synthesis,
purification, and storage and yet readily release H2S under physiological conditions with a proper
trigger. It has been known that different sulfur species have different activities,27-29 so prodrugs
can deliver a single sulfur species is greatly desired for mechanistic studies. In summary, an ideal
H2S prodrug need to have a well-defined mechanism, controllable release rates, triggered release,
and good solubility and stability.27
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Na2S, NaHS

Figure 1.1. Current H2S donors

Currently, there are many H2S donors, which all can satisfy certain standards listed above
and contribute to various important discoveries (Figure 1.1).30-37 However, they also have
obvious disadvantages. Inorganic sulfide salts such as Na2S and NaHS have been widely used in
thiol related signaling pathway studies because of their easy availability.11, 38 However, they will
give a bolus of H2S in an uncontrollable manner. Other donors such as such as GYY4137,
thioamide and 1,2-dithiole-3-thiones release H2S based on hydrolysis, and the effect of their
byproduct associated with H2S release is unclear.39-42 Furthermore, existing H2S donor systems
lack well defined negative controls. Some H2S donors, such as diallyl disulfide, N-mercaptobased donors, and gem-dithiols, need thiol species for activation to release H2S,36, 43-46 which
consume free thiols in biological systems during this process, and those thiol species themselves
are the substrate to produce H2S. For those thiol activated H2S donors, some perthiol
intermediates will be generated during the activation process. Thus, some biological effects may
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come from the perthiol species, not necessarily hydrogen sulfide, making it hard to deconvolute
the experimental results.47-49 Some donors require light activation,50-51 which greatly restricts
their usage in the biological system.
Therefore, there is a need to develop new H2S prodrugs, which directly generate H2S with a
well-defined mechanism and would not consume free thiol species for activation. Many studies
showed that the effects of H2S are dependent not only on H2S donors concentration but also on
the rate of H2S generation.52 So tunable release rate is strongly desired.
We recently build a series of esterase-sensitive H2S prodrugs by taking advantage of
intramolecular lactonization prodrug systems (Scheme 1.1).53 Basically, the nucleophilic
hydroxyl or amino group can be masked as an ester or amide, and the drug, H 2S, can be
conjugated to the carbonyl carbon in the form of a thiol acid. After hydrolysis of the masking
group, the nucleophilic group can attack the carbonyl group and undergo a lactonization reaction,
and thus release the hydrogen sulfide. These esterase-sensitive H2S prodrugs are odorless white
solid and show good water solubility (10 mM in aqueous buffer) and stability (no obvious
decomposition at room temperature for 3 days and -20°C for several months). Through
modiﬁcation of the hydrolysis of ester caging group and the intramolecular lactonization rate,
tunable release rates were achieved. When prodrugs (200 µM) were incubated in PBS with 1
unit/ml esterase at 37°C, their half-lives (based on lactone formation) ranged from 13 to 99 min
with the H2S peak concentration ranging from 95 to13 µM.
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Scheme 1.1 Hydrogen sulfide donors developed in Dr. Binghe Wang’s lab.

1.1.3

Form hydrogen sulfide to perthiol species and hydrogen persulfide

During the past several years, the mechanism behind the various roles of H2S in the
physiological process has become much clearer. Protein S-persulfidation (sometimes described
as S-sulfhydration), in which the thiol group of cysteine (-SH) in protein is converted to a
perthiol group (-SSH), seems to play a critical role.28-29, 54-65 For example, H2S can mediate the
neuroprotective effect of Parkin through sulfhydration (Figure 1.2).57 Parkin is an E3 ubiquitin
ligase, which has neuroprotective effect. S-sulfhydration of C59, C95, and C182 leads to
increased activity. Another example is the ability for H2S to mediate NF-κB’s ability to suppress
TNF-α induced apoptosis by S-sulfhydration (Figure 1.3).61 TNF-α treatment up-regulates the
expression of CSE and thus, elevates the concentration of H2S. H2S then sulfhydrate the C38 of
the p65 subunit of NF-κB (after appropriate oxidation), leading to the increased binding affinity
to ribosomal protein S3 (RPS3), a known coactivator of NF-κB. Such binding augments the
transcriptional activity of NF-κB and stimulates the downstream expression of various
antiapoptotic proteins.
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Figure 1.2 Neuroprotective effect of H2S through S-sulfhydration of Parkin
In looking at the detailed chemistry, it is clear that H2S cannot simply “persulfidate” a
thiol group because H2S is already at its most reductive form in term of the thiol oxidationreduction state.27, 62 Nevertheless, many publications and efforts have convincingly proved that
H2S signals through S-sulfhydration.62 To solve this dilemma, others and we reasoned that some
thiol species at a higher oxidative state than H2S itself such as hydrogen polysulfides (H2Sn, n≥
2) and perthiol (RSnH, n≥2) must be involved in protein S-sulfhydration.59, 61-62, 64 H2S can be
easily oxidized to polysulfide by O2 in the air or by ROS species in the biological system.59, 64, 66
Thus, it is likely that hydrogen polysulfide and/or perthiol derived from H2S are the actual
dominant species in S-sulfhydration.
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Figure 1.3 H2S can mediate the antiapoptotic effect NF-κB by S-sulfhydration.

Endogenous hydrogen polysulfides (H2Sn, n≥2) and perthiol (RSnH, n≥2) have similar
physiological effects with H2S, but with greater potency in some cases and might be the actual
signaling molecule.55, 59, 62 For example, hydrogen polysulfides were found to be able to induce
Ca2+ influx by activating transient receptor potential (TRP)A1 channels in rat astrocytes and are
320 times more potent than H2S.55, 59
Perthiol species like cysteine persulfide (Cys-S-S-H), glutathione persulfide (G-S-S-H)
and hydrogen polysulfide can be generated enzymatically (Figure 1.4).56, 67 From cystine, Cys-SS-H can be formed under the catalysis of CBS or CSE. Cys-S-S-H can go through
disproportionation reaction to form Cys-S-S-S-Cys and H2S, which would generate more
complex perthiol species and hydrogen polysulfide through thiol exchange. Glutathione (GSH)
can also react with Cys-S-S-H to produce glutathione persulfide (G-S-S-H), which can go
through the same process as Cys-S-S-H, leading to more complex perthiol species and hydrogen
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polysulfide. Glutathione reductase can also participate in this process by reducing G-S-S-Sn-G
(n≥1) to G-S-Sn-H. In mouse organs such as liver and heart, the concentrations range of Cys-S-SH and G-S-S-H are measured to be 50-100 μM and 1-5 μM respectively.

Figure 1.4 Enzymatic generation of perthiols and hydrogen polysulfide

The facts that hydrogen polysulfide and perthiol can lead to protein S-sulfhydration and
there are enzymatic pathways to produce such species lend further support to the possibility that
hydrogen polysulfide and perthiol are the actual signaling molecules in certain processes.56, 62
Given the significant role of hydrogen polysulfide and perthiol in protein S-sulfhydration
signaling, there is a need to prepare prodrugs for generating hydrogen polysulfide as single
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species without perturbing cellular redox chemistry. The need for developing hydrogen
polysulfide and perthiol prodrugs derives from their unstable nature.28, 54, 56, 68-69
1.2

Results and discussion
1.2.1

Design of perthiol prodrugs

Perthiol species are highly reactive and unstable,68-69 we decided to trap perthiol in a
relatively stable disulfide form. We then can use a trigger to release perthiol form this disulfide
form. Enzyme-sensitive prodrugs have been widely used in drug delivery. 70-72 We are interested
in designing esterase-sensitive persulfide prodrugs, which are stable under physiological
conditions and can efficiently generate persulfide in the presence of an enzymatic trigger.
Specifically, like the idea of using “hemiacetal” as an unstable intermediate in prodrug design,
we were interested in exploiting the “hydroxyl methyl disulfide” (HOCHRSSR) analog as a key
intermediate in our design. In this design, an ester group is introduced to mask the hydroxyl
group, leading to a stable precursor. Activation of this prodrug thus relies on the cleavage of this
ester bond, resulting in an unstable hydroxyl methyl disulfide intermediate, which would
collapse to give an aldehyde and a persulfide (Scheme 1.2).

Scheme 1.2 General design of persulfide prodrugs, and their release mechanism.

To test our design, persulfide prodrug BW-HP-201 was synthesized by a one-step reaction
between 1,2-dibenzyldisulfane and propionic acid using KMnO4 as the oxidant by following a
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similar literature procedure (Scheme 1.2 and 1.3). BW-HP-201 is a colorless oil without the
characteristic sulfur smell.

Scheme 1.3 Synthesis and structures of persulfide prodrugs.

1.2.2

Validation of perthiol species release and mechanism study

Scheme 1.4 Mechanism study of perthiol release using cysteine
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We first studied the ability for BW-HP-201 to undergo the intended reaction by monitoring
the formation of both benzyl persulfide and benzaldehyde by HPLC. It turned out that the benzyl
persulfide (Scheme 1.4) was not sufficiently stable for detection on an HPLC time scale. This
finding was actually not surprising at all considering the reactivity of perthiol species. This
further affirms the rationale for designing these prodrugs, i.e., without the protection of the
terminal sulfhydryl group and trapping the perthiol in a disulfide form, the persulfide species
would not be stable enough for long-term storage. For detection purpose, we therefore trapped
benzyl persulfide using N-acetyl-cysteine to give compound Cys-S-S-benzyl, the product
between highly reactive benzyl persulfide and N-acetyl-cysteine (Scheme 1.4, Figure 1.5). CysS-S-benzyl is stable for HPLC detection. Specifically, 100 μM BW-HP-201 was treated with
porcine liver esterase (PLE) for 10 min at 37 °C in the phosphate buffered saline (PBS, pH= 7.4)
containing 300 μM N-acetyl-cysteine. The results show that a yield 96 % of benzaldehyde.
However, only 55% of disulfide compound Cys-S-S-benzyl were detected under such this
condition. The almost 100% recovery of benzaldehyde clearly indicates that BW-HP-201 can be
efficiently hydrolyzed and the subsequent intermediate will collapse to form benzaldehyde. We
reasoned the only 55% yield of disulfide compound Cys-S-S-benzyl formation is because the
instability of perthiols species and some of them quickly degrade before they can be trapped. So,
we increased the concentration of N-acetyl-cysteine to 3 mM, we were able to detect about 95%
recovery of disulfide compound Cys-S-S-benzyl. Such results clearly indicated that the release
reaction occurred as designed.
The above studies clearly demonstrated the chemical feasibility of the prodrug activation
and allow for studies of reaction kinetics. Next, it was important to demonstrate persulfide
formation without the added the thiol species.
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Figure 1.5 Mechanism study of perthiol release using N-acetyl-cysteine as trapping
reagent
A), 100 μM BW-HP-201 in PBS. B), 100 μM BW-HP-201 in PBS (4% DMSO) was
incubated with PLE and 3 mM N-acetyl-cysteine at 37 ℃, after 3 hours the mixture was
subjected to HPLC.

For this study, we used dinitrofluorobenzene (DNFB), which was known to trap various
sulfur species (Scheme 1.5).73 Specifically, we incubated 100 μM of the prodrugs with PLE at
37 °C for 10 s and then added 4 mM of DNFB to the mixture. The resulting solution was further
incubated for another 30 min. Then the formation of disulfide compound R-SS-DNFB was
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analyzed by HPLC (Table 1.1). We were able to trap 70 %-82 % of the persulfide released from
the prodrugs. The formation of R-SS-DNFB convincingly demonstrates the release of persulfide
with a high release yield. However, the formation of R-SS-DNFB is still not 100%. We reasoned
this is still because of the instability of persulfide and there is a competition between trapping
and disproportionation reaction of the persulfide released, not because of this system can’t fully
release persulfide.

Scheme 1.5 Persulfide releasing mechanism study by DNFB

To further improve the trapping yield, we changed the trapping temperature from 37 °C
to room temperature. 100 μM of the prodrug BW-HP-201 was incubated with 1unit/ml PLE and
4 mM DNFB at r.t. Under this condition, the trapping yields increased to 82%-93%. Clearly, at a
lower temperature (room temperature vs. 37 °C), the disproportion reaction was slower, allowing
for the improved trapping efficiency. The results demonstrated that the prodrugs could efficiently
afford persulfide for further studies.
Table 1.1 Persulfide released from precursors and trapped by DNFB
Prodrugs

P1

P2

P3

P4

P5

P6

A (%)

79±5

70±4

71±5

80±4

82±5

78±4

B (%)

87±5

80±6

81±5

88±6

93±5

86±5

(A: trapping yield at 37 °C, B: trapping yield at r.t. n= 3, p=0.95)
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In developing reactive thiol species related prodrugs, the releasing rate plays a very
important role.27 The concentration of the reactive thiol species released to the system is not just
determined by the prodrug concentration but also influenced by the releasing rate. So, a donor
system can achieve tunable release rates and thus can control the reactive thiol species
concentration is strongly desired. In our perthiol species release system, the releasing has two
steps:1) the hydrolysis of ester bond to form hydroxyl methyl disulfide intermediate; 2), The
hydroxyl methyl disulfide intermediate collapse to form an aldehyde and push away the perthiol.
For the second step, it happens very fast and would be very hard to control. However, for the
first step, the hydrolysis of an ester by esterase can be well-tuned by changing the hindrance of
the ester group. Thus, prodrugs with different ester group were made using the same method
(Scheme 1.3). The releasing rates of perthiol from prodrugs were determined by measuring the
formation of aldehyde. The half of was aldehyde formation was listed in Table 1.2. The least
bulky prodrug 204 has a half-life of 17 ± 6 s and the bulkiest one 206 has a half-life of 145 ± 12
s with 0.5 unit/ml PLE.
Compound

201

Table 1.2 Kinetic study of perthiol species donors
202
203
204
205
206

A%
96 ± 3
∆
91 ± 4
97 ± 3
97 ± 2
89 ± 6
t1/2 (s)
25 ± 5
12 ± 6*
85 ± 9
17 ± 6
29 ± 6
145 ± 12
Total percentage of aldehyde formation (A%) and 50% aldehyde formation time (t1/2) ∆:
not detectable because of the low boiling point of acetaldehyde; *: 50% BW-HP-202 remaining
at the time of sampling. PLE: 0.5 unit/ml. n= 3 p=0.95.
1.2.3

Perthiol species chemical activity study

This perthiol generation system can provide relatively “pure” persulfide and can be a
really useful tool. This is very important in studying protein S-sulfhydration. In 2009, sulfide
signaling through S-sulfhydration was demonstrated.65 In this discovery, a modified biotin
switch technique was used to detect protein S-sulfhydration. In this assay, S-methyl
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methanethiosulfonate (MMTS) was used as an alkylating reagent and was believed to selectively
react with cysteine and block it while leaving the cysteine perthiol intact (Scheme 1.6A).65 Then
the cysteine perthiol will react with another thiol blocking reagent tethering a biotin. This
method would eventually link a biotin group to the cysteine perthiol on the protein.

Scheme 1.6 A). Previous S-sulfhydration detection method; B), Perthiol activity with
DNFB study

However, the foundation of this probing method was based on the assumption that the
activity between MMTS with RSSH inert (Scheme 1.6). This assumption is very questionable
since perthiol species is more active than thiol species.74-75 To study the reactivity between
MMTS with RSSH, we conducted the reaction between MMTS and the persulfide released from
BW-HP-205 (Scheme 1.6B). Specifically, 100 μM of the prodrug was incubated with 1unit/ml
PLE and 4 mM MMTS at r.t. for 30 min. Then LC-MS was applied to analyze product
formation. BnSSSMe clearly formed as the dominant product, and other possible sulfide
products were only observed in minute quantities (Figure 1.6). The results here clearly
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demonstrated that MMTS could react with persulfide. By taking advantage of the unique
property of our persulfide prodrug system, we reconfirmed that MMTS can efficiently react with
persulfide.

Figure 1.6 HPLC study of reaction between MMTS and perthiol released from BWMD-205

1.2.4

Design of hydrogen persulfide prodrugs

The need for developing H2S2 prodrugs derives from its unstable nature. H2S2 can be
easily reduced to H2S or oxidized to higher valence thiol species.48, 76 We reasoned we can cage
a H2S2 in a di-sulfide form and a disulfide bond is relatively more stable than H2S2, which would
allow us for synthesis, purification, and storage. We then can use a trigger to eliminate the caging
group from both sides, this would allow the efficient release of H2S2. We decided to use the
“trimethyl lock”-facilitated lactonization system as the caging group for prodrug preparation
(Scheme 1.7). Specifically, H2S2 is caged as two thiol acid groups linked by a disulfide bond
(Scheme 1.7). A masked phenol hydroxyl group serves as a latent nucleophile for initiation of
H2S2 release through lactonization.

17

Scheme 1.7 The design of H2S2 prodrugs

An esterase-sensitive H2S2 prodrug, BW-HP-301, was prepared (Scheme 1.8). BW-HP301 is a colorless oil and stable for days at room temperature and months at -20 °C.

Scheme 1.8 Synthesis of BW-HP-301

1.2.5

Validation of hydrogen persulfide release

To prove the proposed mechanism, we first monitor the formation of lactone from BWHP-301 (Scheme 1.9, Figure 1.7). 100 μM BW-HP-301 was incubated with 1 unit/mL PLE in
PBS (2% DMSO) at 37 °C. We observed the time-dependent accumulation of lactone product.

Scheme 1.9 Mechanism of esterase-triggered H2S2 release.
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Figure 1.7 Quantitative detection of lactone byproduct from BW-HP-301.
BW-HP-301 was incubated with 1 unit/mL PLE in PBS (2% DMSO) at 37 °C. n = 3.
We studied whether esterase would promote H2S2 release from BW-HP-301 using a H2S2
fluorescence probe DSP-3 (Scheme 1.10). Thus, BW-HP-301 was incubated with PLE at 37 °C
in phosphate-buffered saline (PBS. pH = 7.4) for 30 min to fully consume BW-HP-301; then 20
μM of DSP-3 was added. Strong fluorescence was observed in experiments with PLE (Figure
1.8), indicating the release of H2S2. In contrast, when BW-HP-301 was incubated without PLE,
negligible fluorescence was detected. Incubation with 200 μM Na2S led to negligible
fluorescence intensity increase, showing the stability of DSP-3 toward H2S. Then we moved
forward to further monitor time-dependent H2S2 generation from the prodrug. Specifically, 40
μM BW-HP-301 was incubated with PLE (1 unit/ml) at 37 °C in PBS. At two-min intervals, an
aliquot of the reaction mixture was taken out and analyzed by DSP-3. The time-dependent
release of H2S2 is shown in Figure 1.10. Basically, H2S2 concentration gradually increased to
about 15 μM within 15 min. Then the concentration of H2S2 slowly decreased probably due to
degradation.

19

Scheme 1.10 H2S2 detection mechanism by DSP-3

Figure 1.8 Detection of H2S2 release from BW-HP-301 by DSP-3.
BW-HP-301 was incubated with 2 units/ml PLE in PBS (2% DMSO) for 30 min and then DSP3 (20 μM) was added. (n = 3). 1) 100 μM BW-HP-301 + PLE; 2) 100 μM Na2S2 + PLE; 3) PLE;
4) 100 μM BW-HP-301; 5) 200 μM Na2S + PLE.

One potential issue for using DSP-3 to detect the released H2S2 form BW-HP-301 is that
DSP-3 is not just sensitive to H2S2, it also sensitive to other hydrogen polysulfide such as H2S3,
H2S4.75 Although based on the mechanism, H2S2 other than other hydrogen polysulfide should be
released, we want to make sure the released hydrogen polysulfide is H2S2. To provide further
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direct evidence of H2S2 release, we used monobromobimane (mBB) to trap H2S2 in a stable
form, mBB-SS-mBB (Scheme 1.11).56, 77

Scheme 1.11 H2S2 trapping experiment by mBB
Using this method, about 68 μM of mBB-SS-mBB was detected from 100 μM prodrug
BW-HP-301 in the presence of 10 units/ml of PLE. The less than 100% conversion could be due
to many reasons, including slow reaction kinetics and stability issues for H2S2. As a reference
point, we also used the same method to trap H2S2 from commercially available Na2S2. About 71
μM of mBB-SS-mBB was detected in 100 μM of Na2S2 solution (Figure 1.9a). The fact that the
prodrug and Na2S2 gave the same results in both the DSP-3 and mBB assays strongly suggest
that the release from the prodrug was nearly 100%, and yet the efficiency of the H 2S2 trapping
reaction was most likely the reason contributing the less than 100% conversion to the trapped
product, mBB-SS-mBB. While H2S2 generated from 100 μM Na2S2 keep decreasing (Figure
1.9b), H2S2 released from 100 μM BW-HP-301 in the presence of 2 units/ml PLE gradually
increased and reached a peak concentration at 25 min.
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Figure 1.9 H2S2 detection by mBB from A) Na2S2 and B) BW-HP-301.

One would expect the sustained concentration of H2S2 to be dependent on the release
rates from a prodrug since the generation and consumption of thiol species in the biological
system is a dynamic process.49 Thus, we wanted to prepare prodrugs with varying release rates.
Specifically, BW-HP-302 was synthesized (Scheme 1.12). The H2S2 release profiles from BWHP-301 and BW-HP-302 are shown in Figure 1.10. From 40 μM of the prodrugs, the fast
releasing one BW-HP-301 had a peak concentration of 15 μM at around 15 min, while BW-HP302 maintained a sustained concentration of about 3 μM. For 100 μM of the prodrug, the halflife was determined to be 24 min for BW-HP-301 and 172 min for BW-HP-302 by HPLC (Table
1.3). The slower release rate of BW-HP-302 was presumably due to the bulkier nature of the
cyclopropanecarbonyl ester, which hinders esterase-mediated hydrolysis.

Scheme 1.12 Structure of BW-HP-302 and 303
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In an effort to broaden the tunability of H2S2 release, a phosphatase-sensitive H2S2
prodrug, BW-HP-303, was synthesized (Scheme 1.12). Alkaline phosphatase (ALP) is widely
used in prodrug work.78-82 Phosphatase-dependent H2S2 release was examined by DSP-3 (Figure
1.10 A). Incubation of BW-HP-303 with 10 units/ml ALP led to strong fluorescence in the
presence of DSP-3, demonstrating H2S2 release. In the absence phosphatase, almost no H2S2 was
detected, indicating the chemical stability of the prodrug. Incubation of DSP-3 with ALP led to
no fluorescence intensity increase either. From 40 μM BW-HP-303, a peak concentration of 10
μM of H2S2 was detected (Figure 1.10B) with a half-life of 28 min with 2 units/ml ALP (Table
1.3).

Figure 1.10 Detection of H2S2 release from BW-HP-303 by fluorescent probe DSP-3
and H2S2 releasing profile form BW-HP-301, BW-HP-302 and BW-HP-303.
A). The concentration of DSP-3 is 20 μM and ALP is 10 units/ml in PBS (1% MeOH),
and the intensities of fluorescence were recorded after 5 min of incubation of DSP-3 with
different substrates at 37°C. Data were acquired at 515 nm with excitation at 490 nm. 1) 100 μM
BW-HP-303 + ALP; 2) 100 μM BW-HP-303; 3) ALP; 4) ALP + 100 μM Na2S2. B). 40 μM
BW-HP-301 and BW-HP-302 with 1 unit/ml PLE in PBS (2% DMSO) and BW-HP-303 with 2
units/ml ALP at 37 °C in PBS (2% MeOH). 20 μM DSP-3 was used.

Table 1.3 The half-lives of various hydrogen persulfide prodrugs
BW-HP-301[a]
BW-HP-302[a]
BW-HP-303[b]
T1/2 (min)
23.9± 1.6
172.5± 9.8
28.5 ± 2.0
a: 100 μM prodrugs in PBS (2% DMSO) were incubated with 1 unit/mL PLE at 37 ℃ b: 100 μM
prodrugs in PBS (1% MeOH) were incubated with 2 units/mL ALP at 37 ℃ (n = 3, p=0.95).
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1.2.6

Direct protein S-sulfhydration by hydrogen persulfide prodrugs

Figure 1.11 Protein S-sulfhydration pathway.
1). cysteine directly reacting with H2S2 or 2). cysteine being oxidized to a sulfenic acid (S-OH)
group by reactive oxygen species (ROS) followed by displacement by H2S

S-sulfhydration is a major sulfur signaling pathway.61-62 We then examined the Ssulfhydration efficiency of the prodrugs on glyceraldehyde 3-phosphate dehydrogenase
(GAPDH), an enzyme known to go through S-sulfhydration process.83 We used a tag-switch
assay to detect S-sulfhydration. Briefly, this tag-switch assay allows a biotin group to be
specifically linked to the sulfhydrated thiol group in the protein so that the sulfhydration level
can be revealed by detecting biotin (Figure1.12).29, 84

Figure 1.12 Protein S-Sulfhydration detection mechanism
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Incubation with 100 μM BW-HP-301 and 10 units/ml PLE at 37℃ led to a significant
increase in GAPDH S-sulfhydration level (Figure 1.13 B and C, line 1) compared to the
untreated group (line 5). In contrast, incubation with 200 μM H2S (line 4) failed to elevate
GAPDH S-sulfhydration level. Protein samples were also treated with 100 μM Na2S2 or 100 μM
H2O2 followed by 100 μM H2S (line 2, 3) to mimic the two endogenous S-sulfhydration process
(Figure 1.11). These two methods both led to significant increase of GAPDH S-sulfhydration.
Such results further affirm that H2S itself is incapable of protein S-sulfhydration. Previously H2S
has been shown to abolish S-sulfhydration by itself.85 The roles that H2S plays in S-sulfhydration
and signaling are dependent on ROS and cellular redox environment.84-86 However, BW-HP-301
was able to induce S-sulfhydration process independent of ROS. So, these H2S2 donors are
important research tools to conduct S-sulfhydration without perturbing the redox balance. Even
with data suggesting the H2S2 being the dominant species released from BW-HP-301, we can't
exclude the possibility that other polysulfide derived from H2S2 degradation may also play a role
in S-sulfhydration because of the unstable nature of H2S2.
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Figure 1.13 BW-HP-301 induce GAPDH S-sulfhydration.
A: Workflow of GAPDH S- sulfhydration process; B and C: GAPDH S-sulfhydration level
assay. GAPDH (2 mg/ml) was subjected to different treatments and the persulfidated protein was
detected by the protein S-sulfhydration switch tag assay; D: GADPH activity assay; All groups
have 10 units/ml PLE and 2% DMSO. (1) 100 μM BW-HP-301; (2) 100 μM Na2S2; (3) 100 μM
H2O2+ 100 μM Na2S; (4) 200 μM Na2S; (5) PLE alone; GADPH was subjected to various
treatment at 37 ℃ for 0.5 h, then its S- sulfhydration level and activity was determined. Values
are means ± SEM. n = 3, **P < 0.01.
It has been a subject of debate as to whether S-sulfhydration leads to increased or
decreased activity of GAPDH.

65, 83

To address this point, GAPDH was treated with the exact

conditions that were used in S-sulfhydration efficacy assay above. Then the enzyme activity was
determined. As shown in Figured 1.13 B and D, GAPDH treated with BW-HP-301, Na2S2, or
H2S and H2O2 together showed elevated protein S-sulfhydration levels and decreased enzyme
activity compared with untreated groups. Meanwhile, H2S alone failed to affect enzyme activity.
GAPDH activity also showed a concentration-dependent decrease in response to BW-HP-301
with a half inhibition concentration of approximately 1 μM (Figure 1.14). Maximal inhibition
was achieved with 5 μM of the BW-HP-301 with about 17% catalytic activity remaining. Further
increase in prodrug concentration to 10 μM did not decrease the enzyme activity further. After
treatment with BW-HP-301, GAPDH was treated with 2 mM DTT at r.t. for 2 h, which should
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reduce the S-sulfhydration product to free the thiol group again. Indeed, enzyme activity was
restored to 75-95% of its original activity by DTT treatment. Considering the important roles of
GAPDH, the above results suggest an important role for H2S2 in energy metabolism,
proliferation, and redox balance.

Figure 1.14 Protein S-sulfhydration is a dynamic and reversible process
Concentration-dependent inhibition of GAPDH activity by BW-HP-301. 2 μg/ml GAPDH was
incubated with various concentration of BW-HP-301 at 37 ℃ for 0.5 h with 10 units/ ml PLE,
after which the enzyme activity was determined. Then each group was incubated with 2 mM
DTT at r.t. for 2 h, after which the GAPDH activity was measured.

In conclusion, we provide a general strategy to deliver perthiol species and H2S2 prodrugs
with the well-defined release mechanism. Secondly, controllable release patterns and tunable
release rates have been achieved. Such perthiol species and H2S2 delivery system can be used to
probe some key issues in the protein S-sulfhydration pathway. This novel series of perthiol
species and H2S2 prodrugs should be important research tools for future studies.

27

1.3

Experimental section
1.3.1

General information

All solvents were of reagent grade and were purchased from Fisher Scientific and
Aldrich. Reagents and were purchased from Aldrich, Oakwood, or VWR. The stationary phase
of chromatographic purification silica (230 × 400 mesh, Sorbtech). Silica gel TLC plate was
purchased from Sorbtech. 1H-NMR (400 MHz) and 13C-NMR (100 MHz) spectra were recorded
on a Bruker Avance 400 MHz NMR spectrometer. Mass spectral analyses were performed on an
ABI API 3200 (ESI-Triple Quadruple). HPLC was performed on a Shimadzu Prominence UFLC
(column: Waters C18 3.5 μM, 4.6×100 mm). UV-Vis absorption spectra were recorded on a
Shimadzu PharmaSpec UV-1700 UV-Visible spectrophotometer. Fluorescence spectra were
recorded on a Shimadzu RF-5301PC fluorometer. 96-Well plates were read and recorded on a
PerkinElmer 1420 multi-label counter. Porcine liver esterase was purchased from Aldrich.WSP5 was synthesized following literature procedures.87 CHNS analysis was conducted by Atlantic
Microlab.
1.3.2

Experiment procedure to synthesize perthiol prodrugs

Scheme 1.13 Synthesis of BW-HP-201

BW-HP-201: To a 20-ml vial was added 1,2-dibenzyldisulfane (500 mg, 2.0 mmol), KMnO4
(316 mg, 2.0 mmol) and 4 ml propionic acid. The oil bath was preheated to 140 ℃ and the
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mixture was stirred at this temperature for 5 min and then immediately cooled down to room
temperature. The mixture was diluted with 100 ml ethyl acetate and then washed with 50 ml
brine, 50 ml saturated NaHCO3 and finally 50 ml brine. The organic phase was then dried over
Na2SO4 and the solvent was evaporated under reduced pressure to give the crude product, which
was purified by column chromatography (hexane: ethyl acetate =200:1) to yield a colorless oil
(Rf = 0.7 in hexane: ethyl acetate =20:1). The colorless oil was further subjected to vacuum at
room temperature for 2 h to yield the pure product as a colorless oil (35 mg, 9.5%, 213 mg of
1,2-dibenzyldisulfane was recovered). 1H NMR (MeOD): δ 7.38-7.24 (m, 10H), 6.76 (s, 1H),
3.75 (s, 2H), 2.47 (q, J = 7.6 Hz, 2H), 1.17 (t, J = 7.6 Hz, 3H) ppm.
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C NMR (MeOD): δ 174.4,

138.2, 138.0, 130.6, 130.0, 129.6, 128.6, 128.6, 127.8, 82.8, 44.2, 28.5, 9.4 ppm. HRMS calcd
for C17H18O2S2Na [M+Na]+ 341.0640, found: 341.0643. Elem. Anal.: calcd (%) for C17H18O2S2:
C 64.12, H 5.70, N 0.00, S 20.14; Found C 64.38, H 5.74, N 0.00, S 20.35.

Scheme 1.14 Synthesis of BW-HP-202

BW-HP-202: To a 20-ml vial was added 1,2-diethyldisulfane (244 mg, 2.0 mmol), KMnO4 (316
mg, 2.0 mmol) and 4 ml propionic acid. The oil bath was preheated to 140 ℃ and the mixture
was stirred at this temperature for 5 min and then immediately cooled down to room temperature.
The mixture was diluted with 100 ml ethyl acetate and washed with 50 ml brine, 50 ml saturated
NaHCO3 and then 50 ml brine. The organic phase was dried over Na2SO4 and then evaporated
under reduced pressure to give the crude product, which was purified by column chromatography
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(hexane: ethyl acetate =200:1) to yield a colorless oil (Rf = 0.6 in hexane: ethyl acetate =20:1).
The colorless oil was further subjected to vacuum at room temperature for 2 h to yield the pure
product as a colorless oil (20mg, 9.6%, 113 mg 1,2-diethyldisulfane was recovered). 1H NMR
(CDCl3): δ 5.99 (q, J = 6.4 Hz, 1H), 2.73 (q, J = 7.2 Hz, 2H), 2.35 (q, J = 7.6 Hz, 2H), 1.60 (d, J
= 6.4 Hz, 2H), 1.31 (t, J = 7.2 Hz, 3H), 1.17 (t, J = 7.6 Hz, 3H) ppm.
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C NMR (CDCl3): δ

173.4, 77.6, 33.7, 27.9, 20.3, 14.4, 9.1 ppm. HRMS calcd for C7H14O2S2Na [M+Na]+ 217.0327,
found: 217.0325. Elem. Anal.: calcd (%) for C7H14O2S2: C 43.27, H 7.26, N 0.00, S 33.00;
Found C 43.41, H 7.13, N 0.00, S 32.84.

Scheme 1.15 Synthesis of BW-HP-203

BW-HP-203: To a 20-ml vial was added 1,2-dibenzyldisulfane (500 mg, 2.0 mmol), KMnO4
(316 mg, 2.0 mmol) and 4 ml 3-methylbutanoic acid. The oil bath was preheated to 140 ℃ and
the mixture was stirred at this temperature for 5 min and then immediately cooled down to room
temperature. The mixture was diluted with 100 ml ethyl acetate and washed with 50 ml brine,
50ml saturated NaHCO3 and then 50ml brine. The organic phase was dried over Na2SO4 and
then evaporated under reduced pressure to give the crude product, which was purified by column
chromatography (hexane: ethyl acetate =200:1) to yield a colorless oil (Rf = 0.7 in hexane: ethyl
acetate =20:1). The colorless oil was subjected to vacuum at 70℃ for 2 h to yield the pure
product as a colorless oil (27mg, 7.6 %, 248 mg 1,2-dibenzyldisulfane was recovered). 1H NMR
(CDCl3): δ 7.40-7.31 (m, 8H), 7.25-7.24 (m, 2H), 6.78 (s, 1H), 3.70 (ABq, J = 12.4 Hz, ΔδAB =
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0.04, 2H), 2.34-2.27 (m, 2H), 2.21-2.16 (m, 1H), 0.99 (d, J = 3.2 Hz, 3H), 0.97 (d, J = 3.2 Hz,
3H) ppm.
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C NMR (CDCl3): δ 171.7, 136.7, 136.6, 129.6, 129.1, 128.7, 128.6, 127.8, 126.9,

81.3, 43.6, 43.6, 25.9, 22.6 ppm. HRMS calcd for C19H23O2S2 [M+H]+ 347.1134, found:
347.1303. Elem. Anal.: calcd (%) for C19H22O2S2: C 65.86, H 6.40, N 0.00, S 18.50; Found C
65.99, H 6.40, N 0.00, S 18.33.

Scheme 1.16 Synthesis of BW-HP-204

BW-HP-204: To a 20-ml vial was added 1,2-dibenzyldisulfane (500 mg, 2.0 mmol), KMnO4
(316 mg, 2.0 mmol), CH3COONa (600mg, 7.3 mmol) and 4 ml acetic acid. The oil bath was
preheated to 140 ℃ and the mixture was stirred at this temperature for 5 min and then
immediately cooled down to room temperature. The mixture was diluted with 100 ml ethyl
acetate and washed with 50 ml brine, 50ml saturated NaHCO3 and then 50ml brine. The organic
phase was dried over Na2SO4 and then evaporated under reduced pressure to give the crude
product, which was purified by column chromatography (hexane: ethyl acetate =200:1) to yield a
colorless oil (Rf = 0.7 in hexane: ethyl acetate =20:1). The colorless oil was further subjected to
vacuum at room temperature for 2 h to yield the pure product as a colorless oil (35mg, 10.8 %,
237 mg 1,2-dibenzyldisulfane was recovered). 1H NMR (CDCl3): δ 7.40-7.29 (m, 9H), 7.26-7.24
(m, 1H), 6.78 (s, 1H), 3.73 (ABq, J = 12.0 Hz, ΔδAB = 0.04, 2H), 2.18 (s, 3H) ppm.
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C NMR

(CDCl3): δ 169.6, 136.6, 136.5, 129.6, 129.2, 128.7, 128.7, 127.8, 126.9, 81.6, 43.6, 21.3 ppm.
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HRMS calcd for C16H16O2S2Na [M+Na]+ 327.0484, found: 327.0494. Elem. Anal.: calcd (%)
for C16H16O2S2: C 63.13, H 5.30, N 0.00, S 21.06; Found C 63.23, H 5.30, N 0.00, S 21.10.

Scheme 1.17 Synthesis of BW-HP-205

BW-HP-205: To a 20 ml vial was added 1,2-dibenzyldisulfane (500 mg, 2.0 mmol), KMnO4
(316 mg, 2.0 mmol) and 4 ml isobutyric acid. The oil bath was preheated to 140 ℃ and the
mixture was stirred at this temperature for 5 min and then immediately cooled down to room
temperature. The mixture was diluted with 100 ml ethyl acetate and washed with 50 ml brine,
50ml saturated NaHCO3 and then 50ml brine. The organic phase was then dried over Na2SO4
and then evaporated under reduced pressure to give the crude product, which was purified by
column chromatography (hexane: ethyl acetate =200:1) to yield a colorless oil (Rf = 0.7 in
hexane: ethyl acetate =20:1). The colorless oil was further subjected to vacuum at 55℃ for 2 h to
yield the pure product as a colorless oil (20 mg, 5.6 %, 233 mg of 1,2-dibenzyldisulfane was
recovered). 1H NMR (CDCl3): δ 7.42-7.29 (m, 9H), 7.26-7.24 (m, 1H), 6.79 (s, 1H), 3.72 (ABq,
J = 12.0 Hz, ΔδAB = 0.05, 2H), 2.73-2.66 (m, 1H), 1.27 (d, J = 7.2 Hz, 3H), 1.24 (d, J = 7.2 Hz,
3H) ppm.
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C NMR (CDCl3): δ 175.6, 136.7, 136.6, 129.6, 129.0, 128.7, 128.6, 127.8, 126.8,

81.2, 43.6, 34.4, 19.1, 19.0 ppm. HRMS calcd for C18H20O2S2Na [M+Na]+ 355.0797, found:
355.0818. Elem. Anal.: calcd (%) for C18H20O2S2: C 65.03, H 6.06, N 0.00, S 19.29; Found C
65.16, H 6.18, N 0.00, S 19.42.
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Scheme 1.18 Synthesis of BW-HP-206

BW-HP-206: To a 20-ml vial was added 1,2-dibenzyldisulfane (1000 mg, 4.0 mmol), KMnO4
(600 mg, 3.8 mmol) and 4 ml isobutyric acid. The oil bath was preheated to 140 ℃ and the
mixture was stirred at this temperature for 5 min and then immediately cooled down to room
temperature. The mixture was diluted with 100 ml ethyl acetate and washed with 50 ml brine,
50ml saturated NaHCO3 and then 50ml brine. The organic phase was then dried over Na2SO4
and then evaporated under reduced pressure to give the crude product, which was purified by
column chromatography (hexane: ethyl acetate =200:1) to yield a colorless oil (Rf = 0.7 in
hexane: ethyl acetate =20:1). The colorless oil was further subjected to vacuum at 70℃ for 2 h to
yield the pure product as a colorless oil (20mg, 5.6 %, 233 mg 1,2-dibenzyldisulfane was
recycled). 1H NMR (CDCl3): δ 7.40-7.30 (m, 8H), 7.26-7.24 (m, 2H), 6.77 (s, 1H), 3.68 (ABq, J
= 12.0 Hz, ΔδAB = 0.05, 2H), 1.29 (s, 9H) ppm.

13

C NMR (CDCl3): δ 177.0, 136.8, 136.6, 129.6,

129.0, 128.7, 128.6, 127.7, 126.8, 81.2, 43.6, 39.2, 27.3ppm. HRMS calcd for C19H22O2S2Na
[M+Na]+ 369.0953, found: 369.0971. Elem. Anal.: calcd (%) for C19H22O2S2: C 65.86, H 6.40, N
0.00, S 18.50; Found C 65.96, H 6.38, N 0.00, S 18.62.
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Scheme 1.19 Synthesis of N-acetyl-S-(benzylthio)cysteine

N-acetyl-S-(benzylthio)cysteine: To a 20-ml vial was added benzyl mercaptan (100 mg,
0.8 mmol), acetylcysteine (130 mg, 0.8 mmol), sodium acetate (131 mg, 1.6 mmol), 4 ml
tetrahydrofuran and 2 ml water. The reaction mixture was stirred for 5 min and then iodine (101
mg, 0.4 mmol) was added. After stirring for another 10 min, the mixture was diluted with 30 ml
ethyl acetate and 10 ml water. To the mixture was then added saturated sodium thiosulfate
solution until the solution became colorless. The organic phase was washed with 10 ml brine and
then concentrated to give the crude product, which was purified by column chromatograph to
yield the pure product as pale yellow oil (Rf = 0.7 in Methanol: Dichloromethane = 1:5, 150 mg,
66 %). 1H NMR (CD3OD): δ 7.36-7.24 (m, 5H), 4.64 (dd, J = 8.8 Hz, J = 4.4 Hz, 1H), 3.93
(ABq, J = 12.8 Hz, ΔδAB = 0.02, 2H), 2.89 (dd, J = 14.0 Hz, J = 4.4 Hz, 1H), 2.71 (dd, J = 14.0
Hz, J = 8.8 Hz, 1H), 1.99 (s, 3H) ppm.

C NMR (CD3OD): δ 173.6, 173.3, 138.8, 130.5, 129.6,

13

128.5, 53.0, 44.1, 40.5, 22.4 ppm. HRMS calcd for C12H16NO3S2+ [M+H]+: 286.0566, found:
286.0569.
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Scheme 1.20 Synthesis 1-benzyl-2-(2,4-dinitrophenyl)disulfane

1-benzyl-2-(2,4-dinitrophenyl)disulfane (a): To a solution of 2,4-Dinitro-1-fluorobenzene
(DNFB, 186mg, 1mmol), 1,2-dibenzyldisulfane (50mg, 0.2 mmol) in 3 ml chloroform was added
a solution of potassium thiolacetate (116mg , 1mmol) in 1ml DMF. The reaction was stirred at r.t
for 15 min. Then compound phenylmethanethiol (500mg, 4mmol) was added to the reaction
mixture. The reaction was stirred at r.t for another 10 min, then iodine (259mg, 1mmol) was
added to the reaction mixture. The reaction mixture was stirred at r.t for 2 h, diluted with ethyl
acetate (30 ml), and washed with 1N HCl (20 ml), H2O (20 ml) and brine (10 ml). The organic
layer was dried over NaSO4 and solvent was removed by rotavapor to afford a crude product,
which was purified by column chromatography (Rf = 0.6 in hexane: ethyl acetate =10:1) to yield
the pure product as a yellow solid (31 mg, 10%). 1H NMR (CDCl3): δ 8.97 (d, J = 2.4 Hz, 1H),
8.13 (dd, J =2.4 Hz, H= 9.2 Hz, 1H), 8.04 (d, J = 9.2 Hz, 1H), 7.13-7.25(m, 5H), 4.00(s, 2H). 13C
NMR (CDCl3): δ 146.1, 145.2, 144.9, 135.5, 129.3, 128.9, 128.8, 128.1, 126.6, 121.1, 43.5.
HRMS calcd for C13H10AgN2O4S2+ [M+Ag]+: 428.9127, found: 428.9132 .
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Scheme 1.21 Synthesis 1-(2,4-dinitrophenyl)-2-ethyldisulfane

1-(2,4-dinitrophenyl)-2-ethyldisulfane: Following the same procedure for preparing
compound b, the product was obtained as a yellow solid (Rf = 0.5 in hexane: ethyl acetate
=10:1,15 mg, 6%). 1H NMR (CDCl3): δ 9.12 (d, J= 2.4 Hz, 1H), 8.54 (d, J= 8.8 Hz, 1H), 8.47
(dd, J= 2.4 Hz, J= 8.8 Hz, 1H), 2.82 (q, J= 6.4 Hz, 2H), 1.36 (t, J= 6.4 Hz, 2H).
(CDCl3):

13

C NMR

δ 147.0, 145.6, 145.2, 128.9, 127.4, 121.8, 32.7, 14.5. HRMS calcd for

C8H8AgN2O4S2+ [M+Ag]+: 366.8971, found: 366.8979.
1.3.3

Experiment procedure to study perthiols release form its donors

Stock solution preparation: perthiol donors stock solution: perthiol donors were dissolved in
DMSO to afford 5 mM stock solutions. Disulfide compound stock solution: Compound a and b
were dissolved in DMSO to afford 5 mM stock solutions. Esterase stock solution: Esterase (18
units/mg esterase from porcine liver, PLE, Aldrich, E3019) was dissolved in phosphate buffer
(PBS, pH 7.4) to afford PLE stock solution. DNFB stock solution: DNFB was dissolved in
DMSO to afford a 200 mM stock solution.
HPLC with Method A: mobile phase A (10 mM NaH2PO4 in water, pH= 5.0) and mobile
phase B (ACN), flow rate: 1 ml/min, running time: 25min, the gradient elution method: 30% B
from 0 to 8 min, 30% to 95% B from 8 to 15 min, 95% B from 15 to20 min, 95% to 30% B from
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20 to 24 min, 30% B from 24 to 25 min. Detection wavelength: 254 nm. Column: Waters C18
3.5 μM, 4.6×100 mm. Injection volume: 20 µl
HPLC with Method B: mobile phase A (H2O) and mobile phase B (ACN), flow rate:
1ml/min, running time: 25min, the gradient elution method: 30% B from 0 to 8 min, 30% to 95%
B from 8 to 15 min, 95% B from 15 to 20 min, 95% to 30% B from 20 to 24 min, 30% B from
24 to 25 min. Detection wavelength: 254 nm. Column: Waters C18 3.5 μM, 4.6×100 mm.
Injection volume: 200 µL
HPLC with Method C: mobile phase A (H2O, pH = 2.8 with CF3COOH) and mobile
phase B (ACN), flow rate: 1ml/min, running time: 35min, the gradient elution method: 30% B
from 0 to 10 min, 30% to 80% B from 10 to 25 min, 80% to 30% B from 25 to 35 min. Detection
wavelength: 254 nm. Column: Waters C18 3.5 μM, 4.6×100 mm. Injection volume: 200 µl.
Various

perthiol

prodrugs

releasing

kinetic

measurement

and

half-life

determination. Various perthiol prodrugs were incubated with 0.5 unit/ml PLE in PBS at 37°C.
At each time point, 200 μl of the reaction solution was taken into a 1.5 mL vial containing 600 μl
acetonitrile (ACN). The mixture was incubated in an acetone-dry ice bath (-78 °C) for 5 min and
centrifuged for 10 min (14.5 × 1000 rpm). The supernatant was analyzed by HPLC with method
A.

compound

201

Table 1.4 Retention times of various perthiol prodrugs
202 203
204
205
206
Benzaldehyde 6a

6b

Time /min

15.9

14.3

15.4

16.6

15.2

16.3

Perthiol release study by N-acetyl-cysteine.

16.6

5.8

14.7

To a 20 ml vial was added 1.9 ml PLE stock

solution (5 unit/ml) and 40 μl N-acetyl-cysteine. Then 40 μl BW-HP-201 (5 mM in DMSO) was
added. The solution was incubated at 37 ºC for 3h. The 200 μl of the reaction solution was taken
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into a 1.5 ml vial containing 600 μl acetonitrile (ACN). The mixture was incubated in an
acetone-dry ice bath (-78 °C) for 5 min and centrifuged for 10 min (14.5 × 1000 rpm). The
supernatant was analyzed by HPLC with method C.

Table 1.5 Reaction conditions of perthiol trapping experiment by N-acetyl cysteine

Condition

PLE stock

Acetylcysteine

BW-HP-

Final

solution

stock solution

201 (5

Acetylcysteine

mM)

concentration

(5unit/ml)
1

1.9 ml

40 µl 150mM

40 µl

0.3 mM

2

1.9 ml

40 µl 15mM

2 µl

3 mM

Persulfide trapping reaction by DNFB: To a 20 ml vial was added 5 ml PLE stock
solution (1 unit/ml). The solution was incubated at 37 ºC for 30 min, then 100 µl 5 mM perthiol
donors stocks were added to the mixture. After 10 s, 100 µl 200 mM DNFB stock solution was
added. The reaction mixture was stirred at 37 ºC for another 30 min. 200 µl reaction mixture was
taken out for HPLC sample preparation.
1.3.4

LC-MS studies of persulfide reactivity with S-methyl methanethiosulfonate
(MMTS).

Sample preparation: To a 20 ml vial was added 5 ml PBS containing 1unit/ml PLE, 100
µl BW-HP-205 stock solution (5 mM in DMSO), and 100 µl MMTS (200mM in DMSO). The
mixture was stirred at r.t for 30min. Then 200 µl of the reaction mixture was taken out and added
to a vial containing 600 µl ACN. Then the mixture was centrifuged for 4 min (14.5 × 1000 rpm).
The supernatant was analyzed by HPLC with method B. The fraction at 15.3 min retention time
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was collected. 1μl AgNO3 (1mg/ml in ACN) solution was added to the fraction, and the mixture
was injected into the MS for analysis.

The HRMS results of these compounds are shown below.
Table 1.6 HRMS of sulfide compounds

Compound

Formula

Calcd.

Found

[BnSSMe+Ag]+

C8H10AgS2+

276.9269

276.9273

[BnSSSMe+Ag]+

C8H10AgS3+

308.8990

308.8997

[BnSSBn+Ag]+

C14H14AgS2+

352.9582

352.9588

[BnSSSBn+Ag]+

C14H14AgS3+

384.9303

384.9307

1.3.5

Experiment procedure to synthesize hydrogen persulfide prodrugs

Synthesis of 3-(2-acetoxy-4,6-dimethylphenyl)-3-methylbutanoic dithioperoxyanhydride (BWHP-301). To a solution of 3-(2-acetoxy-4,6-dimethylphenyl)-3-methylbutanethioic S-acid (BWMD-101, 90 mg, 0.32 mmol) and CH3COONa (26 mg, 0.32 mmol) in THF (2 ml) and H2O (1
ml) was added I2 (41 mg, 0.16 mmol) at room temperature. The mixture was stirred at room
temperature for 5 min. H2O (20 ml) was added and the mixture was extracted with ethyl acetate
(2 × 10 ml). The combined organic phase was washed by saturated sodium thiosulfate aqueous
solution, dried over anhydrous Na2SO4, and then evaporated under reduced pressure to give the
product (90 mg, 100%). 1H NMR (CDCl3): δ 6.80 (d, J = 2.0 Hz, 2H), 6.60 (s, J = 2.0 Hz, 2H),
3.25 (s, 4H), 2.51 (s, 6H), 2.31 (s, 6H), 2.26 (s, 6H), 1.56 (s, 12H). 13C NMR (CDCl3): δ 191.3,
170.0, 149.6, 138.0, 136.8, 132.9, 132.7, 123.3, 55.2, 40.1, 31.3, 25.5, 22.1, 20.4. HRMS calcd
for C30H38O6S2Na [M+Na]+ 581.2002, found: 581.2002.

39

Scheme 1.22 Synthesis of BW-HP-302
Synthesis

of

3-(2-((cyclopropanecarbonyl)oxy)-4,6-dimethylphenyl)-3-methylbutanoic

dithioperoxyanhydride (BW-HP-302). To a solution of 3 3-(2-((cyclopropanecarbonyl)oxy)-4,6dimethylphenyl)-3-methylbutanethioic S-acid (BW-HP-102, 165 mg, 0.53 mmol) and
CH3COONa (43 mg, 0.53 mmol) in THF (2 ml) and H2O (1 ml) was added I2 (68 mg, 0.27 mol)
at room temperature. The mixture was stirred at room temperature for 5 min. H2O (20 ml) was
added and the mixture was extracted with ethyl acetate (2 × 10 ml). The combined organic phase
was washed by saturated sodium thiosulfate aqueous solution, dried over anhydrous Na2SO4, and
then evaporated under reduced pressure to give the product (145 mg, 88%).1H NMR (CDCl3): δ
6.78 (d, J = 1.6 Hz, 2H), 6.59 (d, J = 1.6 Hz, 2H), 3.26 (s, 4H), 2.50 (s, 6H), 2.21 (s, 6H), 1.88
(m, 2H), 1.57 (s, 12H), 1.16 (m, 4H), 1.02 (m, 4H), 1. 13C NMR (CDCl3): δ 191.4, 174.0, 149.8,
137.9, 136.6, 133.0, 132.6, 123.3, 55.5, 40.2, 31.4, 25.6, 20.4, 13.7, 9.2. HRMS calcd for
C34H43O6S2 [M+H]+ 611.2496, found: 611.2499.
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Scheme 1.23 Synthesis of BW-HP-303.
Reagents and conditions (i) t-BuOK, DCM, 0 ℃- rt, 12 h, 98%; (ii) AcOH/H2O, THF, rt, 4 h,
84%; (iii) Pyridinium chlorochromate (PCC), DCM, rt, 2 h, 82%; (iv) NaClO2/NaH2PO4, 2methylbut-2-ene, t-BuOH, rt, 2 h, 66%; (v) Lawesson’s reagent, DCM, microwave, 6 min; (vi),
I2, CH3COONa, THF/H2O, rt, 5 min, 59% for 2 steps; (vii) TMSBr, CHCl3, rt, 8 h, 100%.

Synthesis of 2-(4-((tert-butyldimethylsilyl)oxy)-2-methylbuta58n-2-yl)-3,5-dimethylphenyl
diethyl phosphate (3). To a solution of 2-(4-((tert-butyldimethylsilyl)oxy)-2-methylbutan-2-yl)3,5-dimethylphenol (1, 4 g, 12.4 mmol) and t-BuOK ( 2 g, 18.6 mmol) in DCM (40 ml) was
added dropwise diethyl phosphorochloridate (2, 2.6 ml, 18.6 mmol) in 20 mL DCM at 0 ℃
during a period of 10 min. The mixture was allowed to warm to room temperature and was
stirred for an additional 12 h. Then the reaction was quenched with the addition of H2O (100 ml)
and the mixture was extracted with ethyl acetate (2 × 100 ml). The combined organic phase was
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dried over anhydrous Na2SO4 and evaporated under reduced pressure to give the crude product,
which was purified by column chromatography (silica gel, hexane: ethyl acetate =10:1) to give a
colorless oil (5.56 g, 98%). 1H NMR (CDCl3): δ 7.11 (s, 1H), 6.69 (s, 1H), 4.22 – 4.18 (m, 4H),
3.48 (t, J = 7.6 Hz, 2H), 2.48 (s, 3H), 2.21 (s, 3H), 2.08 (t, J = 7.6 Hz, 2H), 1.52 (s, 6H), 1.311.34 (m, 6H), 0.82 (s, 9H), -0.05 (s, 6H).
136.1, 132.7 (d, J

c,p

13

C NMR (CDCl3): δ 150.5(d, J

= 8.1 Hz), 130.9, 118.7 (d, J

c,p

c,p

= 5.7 Hz), 138.5,

= 2.1 Hz), 77.5, 77.2, 76.8, 64.4 (d, J

5.9 Hz), 61.1, 45.8, 39.6, 32.2, 26.0, 25.7, 20.5, 18.3, 16.2 (d, J

c,p

= 6.8 Hz), -5.26.

31

c,p

=

P NMR

(CDCl3): δ -7.61. HRMS calcd for C23H43O5PSi [M+H]+459.2690, found: 459.2695.

Synthesis of diethyl (2-(4-hydroxy-2-methylbutan-2-yl)-3,5-dimethylphenyl) phosphate
(4). To a solution of 2-(4-((tert-butyldimethylsilyl)oxy)-2-methylbutan-2-yl)-3,5-dimethylphenyl
diethyl phosphate (3, 5.46 g, 11.9 mmol) in tetrahydrofuran (THF, 60 mL) was added H2O (60
mL) and AcOH (180 ml) immediately. The mixture was stirred at r.t. for 2 h. Then solvents were
evaporated under reduced pressure, and the crude product was purified by silica gel column
chromatography (DCM: ethyl acetate = 20:1) to give a colorless oil (3.4 g, 84%). 1H NMR
(CDCl3): δ 7.03 (s, 1H), 6.68 (s, 1H), 4.15-4.22 (m, 4H), 3.46 (t, J = 7.6 Hz, 2H), 2.62 (s, 1H),
2.45 (s, 3H), 2.18 (s, 3H), 2.09 (t, J = 7.6 Hz, 2H), 1.48 (s, 6H), 1.30-1.34 (m, 6H).

13

C NMR

(CDCl3): δ 150.3(d, J c,p = 6.8 Hz), 138.5, 136.2, 132.6 (d, J c,p = 7.7 Hz), 131.1, 118.9 (d, J c,p =
2.1 Hz), 77.5, 77.2, 76.8, 64.5 (d, J c,p = 5.9 Hz), 60.4, 46.0, 39.5, 32.1, 25.6, 20.3, 16.1 (d, J c,p =
6.7 Hz). 31P NMR (CDCl3): δ -7.28. HRMS calcd for C17H29O5P [M+H]+345.1825, found:
345.1831.
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Synthesis of 3,5-dimethyl-2-(2-methyl-4-oxobutan-2-yl)phenyl diethyl phosphate (5). To a
solution of PCC (4.0 g, 20.0 mmol) in DCM (30 ml) was added dropwise diethyl (2-(4-hydroxy2-methylbutan-2-yl)-3,5-dimethylphenyl) phosphate (4, 3.4 g, 10 mmol) in DCM (50 mL) at
room temperature. After stirring for 2 h, the mixture was directly subjected to column
chromatography (DCM: ethyl acetate =10:1) to obtain the pure product as colorless oil (2.85 g,
82%). 1H NMR (CDCl3): δ 9.52 (t, J = 2.4 Hz, 1H), 7.12 (s, 1H), 6.72 (s, 1H), 4.21 – 4.15 (m,
4H), 2.90 (d, J = 2.4 Hz, 2H), 2.49 (s, 3H), 2.21 (s, 3H), 1.57 (s, 6H), 1.31 (t, J = 7.2 Hz, 6H).
C NMR (CDCl3): δ 203.1, 149.9 (d, J c,p = 6.7 Hz), 138.0, 136.9, 131.2 (d, J c,p = 7.0 Hz), 119.0

13

(d, J c,p = 2.0 Hz), 64.5 (d, J c,p = 5.8 Hz), 56.7, 38.4, 31.7, 25.7, 20.4, 16.1 (d, J c,p = 6.6 Hz). 31P
NMR (CDCl3): δ -7.35. HRMS calcd for C17H27O5P [M+H]+343.1669, found: 343.1671.

Synthesis of 3-(2-((diethoxyphosphoryl)oxy)-4,6-dimethylphenyl)-3-methylbutanoic acid
(6). To a solution of 3,5-dimethyl-2-(2-methyl-4-oxobutan-2-yl)phenyl diethyl phosphate (5, 950
mg, 2.81 mmol) in t-BuOH (15 ml) and 2-methylbut-2-ene (3 ml), NaClO2 (380 mg, 4.2 mmol)
in 0.67 M NaH2PO4 (3 ml) was added dropwise at room temperature. After stirring for 2 h, the
reaction mixture was quenched with 1M HCl (20 mL), and the mixture was extracted with ethyl
acetate (2 × 30 ml). The combined organic phase was dried over anhydrous Na2SO4 and then
evaporated under reduced pressure to give the crude product, which was purified by column
chromatography (DCM: ethyl acetate =10:1) to yield a colorless oil (670 mg, 66%). 1H NMR
(CDCl3): δ 7.06 (s, 1H), 6.69 (s, 1H), 4.23 – 4.14 (m, 4H), 2.90 (s, 2H), 2.49 (s, 3H), 2.20 (s,
3H), 1.60 (s, 6H), 1.31 (t, J = 7.2 Hz, 6H). 13C NMR (CDCl3): δ 176.8, 150.2 (d, J c,p = 6.8 Hz),
138.5, 136.4, 132.0 (d, J

c,p

= 7.8 Hz), 131.2, 118.8 (d, J

c,p

= 2.0 Hz), 64.7 (d, J

c,p

= 5.9 Hz),
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47.4, 39.2, 31.7, 25.6, 20.4, 16.1 (d, J c,p = 6.8 Hz). 31P NMR (CDCl3): δ -7.59. HRMS calcd for
C17H27O6P [M-H]-357.1472, found: 357.1417.

Synthesis

of

dithioperoxyanhydride

3-(2-((diethoxyphosphoryl)oxy)-4,6-dimethylphenyl)-3-methylbutanoic
(7).

To

a

solution

of

3-(2-((diethoxyphosphoryl)oxy)-4,6-

dimethylphenyl)-3-methylbutanoic acid (6, 180 mg, 0.50 mmol) in DCM (5 ml) was added
Lawesson’s reagent (101 mg, 0.25 mmol). The mixture was heated in a microwave at 100 ℃ for
6 min. The mixture was directly subjected to column chromatography (hexane: ethyl acetate
=5:1) to obtain the pure product as colorless oil. The colorless oil was immediately dissolved in
THF (2 ml) and H2O (1 ml). Then CH3COONa (26 mg, 0.32 mmol) and I2 (40 mg, 0.16 mmol)
were added at room temperature. The mixture was stirred at room temperature for 5 min. H 2O
(20 ml) was added and the mixture was extracted with ethyl acetate (2 × 10 ml). The combined
organic phase was washed by saturated sodium thiosulfate aqueous solution, dried over
anhydrous Na2SO4 and then evaporated under reduced pressure to give the product (110 mg,
59% for 2 steps). 1H NMR (CD3OD): δ 7.10 (s, 2H), 6.68 (s, 2H), 4.24 – 4.14 (m, 8H), 3.33 (s,
4H), 2.46 (s, 6H), 2.21 (s, 6H), 1.59 (s, 12H), 1.36-1.29 (m, 12H).
150.3 (d, J

c,p

= 6.7 Hz), 138.3, 136.8, 131.2 (d, J

c,p

13

C NMR (CDCl3) δ191.6,

= 1.9 Hz), 131.1, 118.6 (d, J

c,p

= 2.0 Hz),

64.7(d, J c,p = 5.8 Hz), 55.4, 40.5, 31.6, 25.7, 20.6, 16.3 (d, J c,p = 6.8 Hz). 31P NMR (CDCl3) δ 7.77. HRMS calcd for C34H53O10P2S2 [M+H]+ 747.2550 found: 747.2529.

Synthesis

of

3-(2,4-dimethyl-6-(phosphonooxy)phenyl)-3-methylbutanoic

dithioperoxyanhydride (BW-HP-303). To a solution of 3-(2-((diethoxyphosphoryl)oxy)-4,6dimethylphenyl)-3-methylbutanoic dithioperoxyanhydride (7, 160 mg, 0.21 mmol) in anhydrous
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CHCl3 (1 ml) was added TMSBr (328 μL , 2.5 mmol) dropwise at room temperature under N2.
The mixture was stirred at room temperature for 8 h, after which 0.2 mL H2O and 2 mL MeOH
were added and the mixture was stirred at room temperature for another 30 min. All the solvents
were evaporated under reduced pressure to afford a yellow solid (131 mg, 100%). 1H NMR
(CD3OD): δ 7.11 (s, 2H), 6.69 (s, 2H), 3.40 (s, 4H), 2.46 (s, 6H), 2.21 (s, 6H), 1.60 (s, 12H). 13C
NMR (CD3OD): δ 193.3, 150.9 (d, J c,p = 6.3 Hz), 139.4, 137.6, 132.3 (d, J c,p = 6.3 Hz), 131.5,
119.5 (d, J c,p = 2.4 Hz), 56.0, 41.4, 32.1, 25.9, 20.5. 31P NMR (CD3OD): δ -1.22. HRMS calcd
for C26H36O10P2S2 [M+H]+ 635.1298 found: 635.1282.

Scheme 1.24 Synthesis of mBB-SS-mBB

Synthesis of 5,5'-(disulfanediylbis(methylene))bis(2,3,6-trimethyl-1H,7H-pyrazolo[1,2a]pyrazole-1,7-dione) (mBB-SS-mBB). To a solution of monobromobimane (27 mg, 0.1 mmol)
in CH3CN (2 ml) was added Na2S2 in 0.5 mL H2O and 0.5 mL CH3CN (5.5 mg, 0.05 mmol)
dropwise at room temperature. The mixture was stirred at room temperature for 0.5 h, after
which all the solvents were evaporated under reduced pressure to afford a crude product. The
crude product was purified by column chromatography (DCM: MeOH =50:1) to yield a yellow
solid (12 mg, 54%). 1H NMR (CDCl3): δ 3.87 (s, 4H), 2.35 (s, 6H), 1.91 (s, 6H), 1.84 (s, 6H). 13C
NMR (CDCl3): δ 160.7, 160.0, 146.0, 144.4, 116.2, 113.8, 32.5, 12.1, 7.6, 7.0. HRMS calcd for
C20H23N4O4S2 [M+H]+ 447.1155 found: 447.1150.
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1.3.6

Experiment procedure to measure hydrogen persulfide

Below described the detection of H2S2 release from H2S2 prodrugs using fluorescent
probe DSP-3.
BW-HP-301 and 302 stock solution: BW-HP-301 or 302 was dissolved in DMSO to
afford 5 mM. BW-HP-303 was dissolved in MeOH to afford a 10 mM stock solution. Na2S2
stock solution (Freshly prepared before use): Na2S2 was dissolved in PBS to afford 5 mM or 10
mM solution. Porcine liver esterase solution: 2 mg esterase (18 units/mg esterase from porcine
liver) was dissolved in 18 ml PBS to provide a 2 units/ml esterase solution; 10 mg esterase was
dissolved in 18 ml PBS to provide a 10 units/mL esterase solution. Phosphatase solution:
Alkaline phosphatase from bovine intestinal mucosa (Aldrich, P0114) was dissolved in PBS to
provide a 10 units/mL phosphatase solution. DSP-3 stock solution: DSP-3 was dissolved in
CH3CN to prepare a 0.5 mM stock solution. CTAB stock solution: CTAB was dissolved in
ethanol to prepare a 5 mM stock solution.
BW-HP-301 (final concentration: 100 μM) or other control compounds was added to
PBS (4 ml) buffer with (2 units/ ml) or without esterase at 37 °C. After incubation for 30 min,
the mixture was cooled down to room temperature. Then 20 μl 5 mM CTAB stock solution and
160 μL DSP-3 stock solution were added. After 5 min at room temperature, the fluorescence
intensity at 515 nm was recorded with excitation at 490 nm.
BW-HP-303 (final concentration: 100 μM) or other control compounds was added to
PBS (4 ml) buffer with phosphatase (10 units/ml) or without phosphatase at 37 °C. After
incubation for 5 min, the mixture was cooled down to room temperature. Then 20 μl of 5 mM
CTAB stock solution and 160 μl DSP-3 stock solution were added. After 5 min at room
temperature, the fluorescence intensity at 515 nm was recorded with excitation at 490 nm.
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Below described the detection of H2S2 release from H2S2 prodrugs by
monobromobimane (mBB).
BW-HP-301 stock solution: BW-HP-301 was dissolved in DMSO to afford 5 mM stock
solution. BW-HP-302 stock solution: BW-HP-302 was dissolved in DMSO to afford 5 mM stock
solution. BW-HP-303 stock solution: BW-HP-303 was dissolved in MeOH to afford a 10 mM
stock solution. Na2S2 stock solution (Freshly prepared before use): Na2S2 was dissolved in PBS
to afford 5 mM solution. Porcine liver esterase solution: 5 mg esterase (18 units/mg esterase
from porcine liver) was dissolved in 9 mL PBS to provide a 10 units/ml esterase solution; 2 mg
esterase (18 units/mg esterase from porcine liver) was dissolved in 18 ml PBS to provide a 2
units/mL esterase solution. Monobromobimane (Aldrich, B4380) was dissolved in CH3CN to
make 10 mM solution.
Group 1: To 3 ml PBS with 10 units/mL PLE was added 60 μl 5 mM BW-HP-301;
Group 2: To 3 ml PBS with 2 units/mL PLE was added 60 μl 5 mM BW-HP-301;
Group 3: To 2.94 ml PBS with 10 units/mL PLE was added 60 μl 5 mM Na2S2 and 60 μL
DMSO;
Group 4: To 3 ml PBS with 10 units/mL PLE was added 60 μl 5 mM BW-HP-302;
Group 5: To 3 ml PBS with 10 units/mL ALP was added 30 μl 10 mM BW-HP-303;
At different time points, 75 μl reaction mixture was extracted and mixed with 75 μl 10
mM mBB in CH3CN. The reaction mixture was allowed to react at r.t. for 2 h. The mixture (14.5
×1000 rpm, 90 seconds) was centrifuged, and the supernatant was used for HPLC analysis of
mBB-SS-mBB formation. 20 μl of each sample was injected into Shimadzu Prominence UFLC
(column: Waters C18 3.5 μM, 4.6×100 mm, injection loop volume: 20μl). The mobile phase was
acetonitrile (ACN)/H2O (with 0.05% trifluoroacetic acid) with ratios defined in the table below.
Table 1.7 Elution condition for mBB-SS-mBB
Elution conditions
23%ACN, 0~18 min;
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23%~80% ACN, 18~24 min;
80%~23% ACN, 24~30 min..
Retention time of mBB-

15.5 ± 0.2

SS-mBB (min)

Below described the quantitative detection of H2S2 release from H2S2 prodrugs using
fluorescent probe DSP-3
BW-HP-301 and 302 stock solution: BW-HP-301 or 302 was dissolved in DMSO to
afford 2 mM stock solution. BW-HP-303 stock solution: BW-HP-303 was dissolved in MeOH to
afford 2 mM stock solution. Na2S2 stock solution (Freshly prepared before use): Na2S2 was
dissolved in PBS to afford 5 mM solution. Porcine liver esterase solution: 1 mg esterase (18
units/mg esterase from porcine liver) was dissolved in 18 mL PBS to provide a 1 unit/ml esterase
solution. Phosphatase solution: Alkaline phosphatase from bovine intestinal mucosa was
dissolved in PBS to provide a 2 units/ml phosphatase solution. DSP-3 stock solution: DSP-3 was
dissolved in CH3CN to prepare a 0.5mM stock solution. CTAB stock solution: CTAB was
dissolved in ethanol to prepare a 5 mM stock solution.

Standard Curve for BW-HP-301 and 302: Na2S2 stock solution was added to 10 ml PBS
(with 1 unit/ml porcine liver esterase and 2 % DMSO) to afford 0 μM, 2 μM, 4 μM, 8 μM, 16
μM and 32 μM solution. Then 300 μl solution was immediately extracted and mixed with 300 μl
CH3CN containing 25 μM CTAB and 20 μM DSP-3. The mixture was incubated at room
temperature for 5 min, then fluorescence intensity at 515 nm was recorded with excitation at 490
nm.
Standard Curve BW-HP-303: Na2S2 stock solution was added to 10 ml PBS (with 2
units/mL alkaline phosphatase and 2 % MeOH) to afford 0 μM, 2 μM, 4 μM, 8 μM, 16 μM and
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32 μM solution. Then 300 μl solution was immediately extracted and mixed with 300 μl CH3CN
containing 25 μM CTAB and 20 μM DSP-3. The mixture was incubated at room temperature for
5 min, the fluorescence intensity at 515 nm was recorded with excitation at 490 nm.
For BW-HP-301 and 302: To 10 mL PBS (with 1 unit/ml PLE) was added 200 μl of 2
mM BW-HP-301 or BW-HP-302 stock solution. The mixture was incubated at 37°C. At
different time points, 300 μl solution was extracted and immediately mixed with 300 μl CH3CN
containing 25 μM CTAB and 20 μM DSP-3. The mixture was incubated at room temperature for
5 min; then fluorescence intensity at 515 nm was recorded with excitation at 490 nm.
For BW-HP-303: To 10 ml PBS (2 units/mL alkaline phosphatase) was added 200 μl of 2
mM BW-HP-303 stock solution. The mixture was incubated at 37°C. At different time points,
300 μl solution was removed and immediately mixed with 300 μl CH3CN containing 25 μM
CTAB and 20 μM DSP-3. The mixture was incubated at room temperature for 5 min; then
fluorescence intensity at 515 nm was recorded with excitation at 490 nm.

1.3.7

Experiment procedure for HPLC study of hydrogen persulfide release

Lactone formation form BW-HP-301 and 302: BW-HP-301 or BW-HP-302 (final
Conc. 100 μM, 2% DMSO) was added to PBS (10 ml) with 1 unit/ml esterase at 37 °C. 200 μl of
the reaction mixture was taken out at different time points and added into a vial containing 600
μl ethanol at -78 °C for 5 min. The mixture (14.5 ×1000 rpm, 90 seconds) was centrifuged, and
the supernatant was used for HPLC analysis. 20 μl HPLC of each sample was injected into
Shimadzu Prominence UFLC (column: Waters C18 3.5 μM, 4.6×100 mm, injection loop
volume: 20 μl). The mobile phase was acetonitrile (ACN)/H2O (pH = 2.6) with ratios defined in
the table below.
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Table 1.8 HPLC elution conditions for BW-HP-301 and BW-HP-302
BW-HP-301
BW-HP-302
Elution conditions

50%~80% ACN, 0~20min;

50%~80% ACN, 0~20min;

80%~50% ACN, 20~25 min;

80%~90% ACN, 20~30 min;
90%~50% ACN, 30~40 min;

Retention time of

20.3 ± 0.2

25.6 ± 0.2

7.4 ± 0.2

7.4 ± 0.2

prodrugs (min)
Retention time of
lactones (min)
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Below described the alkaline phosphatase triggered H2S2 release and lactone
formation from BW-HP-303 as monitored with HPLC.
BW-HP-303 (final Conc. 100 μM, 1% MeOH) was added to PBS (10 mL) with 2 units/ml
alkaline phosphatase at 37 °C. 200 μl reaction mixture was taken out at different time points and
added into a vial containing 600 μl ethanol at -78 °C for 5 min. The mixture (14.5 ×1000 rpm, 90
seconds) was centrifuged, and the supernatant was used for HPLC analysis. 20 μl of each sample
was injected into Shimadzu Prominence UFLC (column: Waters C18 3.5 μM, 4.6×100 mm,
injection loop volume: 20μL). The mobile phase was acetonitrile (ACN)/H2O (pH = 3.1) with
ratios defined in the tab below.
Table 1.9 HPLC elution conditions for BW-HP-303
BW-HP-303
Elution conditions

30%~40% ACN, 0~10 min;
40%~60% ACN, 10~15 min;
60%~30% ACN, 15~30 min;

Retention time of prodrugs

22.9 ± 1

(min)
Retention time of lactones

24.3 ± 0.2

(min)

1.3.8

GAPDH S-sulfhydration modification assay.

GAPDH S-sulfhydration modification assay using a tag-switch technique GAPDH
(Sigma, G2267-1KU) was dissolved in PBS to make 5 mg/ml stock solution and then the
solution was incubated with 10 mM DTT (dithiothreitol) at 25 °C for 1 h. Then DTT was
removed using Amicon ultra 10K tube ×3 (UFC501096) and bio-spin column (Thermo, 7K
MWCO; 89882). The final GAPDH concentration was adjusted to 10 mg/ml. PLE was dissolved
in PBS to make final concentration 10 units/ml.
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Group 1: 2 μl of 5 mM BW-HP-301 in DMSO was added to 100 μl 10 units/ml PLE and
the mixture was incubated at 37 °C for 10 min to make sure the full consumption of BW-HP-301
(Confirmed by HPLC). Then 25 μl GAPDH stock solution was added to make 2 mg/ml GAPDH.
The mixture was incubated at 37 °C for 30 min.
Group 2: 2 μl of 5 mM Na2S2 in PBS and 2μl DMSO were added to 100 μl 10 units/ml
PLE. Then 25 μl GAPDH stock solution was added to make 2 mg/ml GAPDH. The mixture was
incubated at 37 °C for 30 min.
Group 3: 1 μl of 10 mM H2O2 in PBS and 2μL DMSO were added to 100 μl 10 units/ml
PLE, then 25 μl GAPDH stock solution was added to make 2 mg/ml GAPDH. The mixture was
incubated at room temperature for 15 min; then 2μl 5 mM Na2S was added and incubated at
room temperature for 15 min.
Group 4: 4 μl of 5mM Na2S in PBS and 2μL DMSO were added to 100 μl 10 units/ml
PLE, then 25 μl GAPDH stock solution was added to make 2mg/ml GAPDH. The mixture was
incubated at 37°C for 30 min.
Group 5: 2 μl of DMSO was added to 100 μl 10 units/mL PLE, then 25 μl GAPDH stock
solution was added to make 2 mg/ml GAPDH. The mixture was incubated at 37°C for 30 min.

After various treatments, 10 μl of 25% SDS (sodium dodecyl sulfate) and 6 μl 200 mM
MSTB-A in DMSO were added. The mixture was incubated at room temperature for 15 min.
Then, all groups were desalted by bio-spin column. The filtrate was collected and 4 μl 50 mM
CN-biotin in DMSO was added. All groups were incubated at room temperature for 1 h and then
were desalted by a bio-spin column. Then 2 μg protein was loaded onto SDS-PAGE
(Polyacrylamide Gel Electrophoresis). Protein samples were mixed with 4 x Laemmli buffer
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(Bio-rad), and then loaded onto 8% polyacrylamide gel. After electrophoresis proteins were
transferred on nitrocellulose membrane using semi-dry system (BioRad, USA), blocked with 3%
BSA for 2 h at room temperature, and incubated with HRP-labelled mouse monoclonal antibiotin antibody (Sigma Aldrich, St. Louis, MO). Signal was visualized using Pierce ECL reagent
(Thermo Scientific, IL, USA) and then the membrane was exposed to x-ray films.
Below described the GAPDH activity measurement after various treatment.
GAPDH (Sigma, G2267-1KU) was dissolved in PBS to make a 5 mg/ml stock solution.
Then the solution was incubated with 1 mM DTT at 25 °C for 1 h. Then DTT was removed
using Amicon ultra 10K tube ×3 (UFC501096) and a bio-spin column (Thermo, 7K MWCO;
89882). The final GAPDH concentration was adjusted to 1 mg/ml. PLE was dissolved in PBS to
give a final concentration of 10 units/ml.
Group 1: 20 μl of 5 mM BW-HP-301 in DMSO was added to 1mL 10 units/ml PLE and
the mixture was incubated at 37 °C for 10 min to ensure full consumption of BW-HP-301
(Confirmed by HPLC). Then 2 μl of GAPDH stock solution was added to make a 2 μg/ml
solution GAPDH. The mixture was incubated at 37 °C for 30 min.
Group 2: 20 μl of 5 mM Na2S2 in PBS and 20 μl DMSO were added to 1mL 10 units/ml
PLE, then 2 μl GAPDH stock solution was added to make 2 μg/ml GAPDH. The mixture was
incubated at 37°C for 30 min;
Group 3: 10 μl of 10 mM H2O2 in PBS and 20μL DMSO were added to 1ml 10 units/ml
PLE, then 2 μl GAPDH stock solution was added to make 2 μg/ml GAPDH. The mixture was
incubated at room temperature for 15 min; then 10 μl 10mM Na2S was added and incubated at
room temperature for 15 min;
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Group 4: 20 μl of 10 mM Na2S in PBS and 20 μl DMSO were added to 1 ml 10 units/ml
PLE, then 2 μl GAPDH stock solution was added to make 2 μg/ml GAPDH. The mixture was
incubated at 37°C for 30 min;
Group 5: 20 μl DMSO was added to 1 ml 10 units/mL PLE, then 2 μl GAPDH stock
solution was added to make 2 μg/ml GAPDH. The mixture was incubated at 37°C for 30 min;
GAPDH activity was determined by literature reported method.65 Briefly, 100 μl of each
extraction sample was mixed with 100 μl GAPDH assay buffer [20 mM Tris-HCl (pH 7.8), 100
mM NaCl, BSA (0.1 mg/ml), 2 mM NAD+ (nicotinamide adenine dinucleotide), 10 mM sodium
pyrophosphate, 20 mM sodium arsenate, and 6 mM glyceraldehyde 3-phosphate]. The formation
of NADH was spectrophotometrically monitored in real time at 340 nm at 37°C.
Below described the GAPDH activity measurement after treated with BW-HP-301
at various concentrations.
20 μl 5 mM BW-HP-301 in DMSO was added to 1ml 10 units/mL PLE (final
concentration of 100 μM) and was incubated 37 °C for 10 min to ensure full consumption of
BW-HP-301 (Confirmed by HPLC). To 1 mL 2 μg/ml GAPDH was added BW-HP-301 stock
solution to achieve various final concentrations (10 μM, 5 μM, 2.5 μM, 1.25 μ, 0.6μM, 0 μM).
Each concentration was balanced to have the same amount PLE and DMSO. The mixture was
incubated at 37 °C for 30 min. Then, each group was divided into two parts. For the first part,
GAPDH activity was determined. For the second part, each group was incubated with 2 mM
DTT at r.t. for 2 h and then GAPDH activity was determined.
To 100 μl 2 mM DTT, Na2S or Na2S2 in PBS was added 100 μl GAPDH assay buffer as
described above. The formation of NADH was spectrophotometrically monitored in real time at
340 nm at 37 °C.
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2

DEVELOPMENT OF BACTERIAL SENSITIZERS FOR ANTIBACTERIAL
COMBINATION THERAPY

2.1

Introduction
2.1.1

Multi-drug resistant bacterial infections

Since the discovery of the first antibiotic in 1928 by Alexander Fleming followed by the
golden era of antibiotics discovery from the 1960s to 1990s, human beings have gained a great
advantage in the fight with bacteria.88-89 During the past decades, we have taken it for granted
that bacterial infections can be effectively treated by antibiotics and mortality caused by bacterial
infections is rare. However, the balance is changing rapidly with the emergence of multi-drug
resistant (MDR) bacteria. Life-threatening infections caused by MDR bacteria pose a great threat
to public health.90-92 According to Centers for Disease Control and Prevention (CDC), at least 2
million people become infected with drug-resistant bacteria and at least 23,000 people die as a
direct result of these infections each year in the United States. The total economic cost of
antibiotic resistance in the U.S. was estimated to be 20 billion a year. Drug-resistant bacteria
have been identified as one of the major public health threats.91-92

Figure 2.1 Bacteria develop resistance to antibiotics by reducing the accessibility of
antibiotics to their target
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Bacteria develop resistance to antibiotics through two major mechanisms: 1) reduced
accessibility of antibiotics to the targets and 2). inactivation of antibiotics.88,

93

For the first

mechanism: reducing accessibility of antibiotics to their targets (Figure 2.1), bacteria can achieve
this by three distinct pathways.88, 94 First, bacteria have their membrane as the barrier to prevent
antibiotic entrance (Figure 2.1, pathway 1).95-97 In Gram-positive bacteria, the barrier is the thick
peptidoglycan layer (cell wall) together with an inner membrane. In Gram-negative bacteria,
there is an added barrier, the outer-membrane,95 with lipopolysaccharides (LPS) being the key
component.
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These barriers shield the antibiotics from their inner targets. The membrane of

Gram-negative bacteria is a stronger barrier than that of Gram-positive bacteria.88-89, 95 Thus,
antibiotics are divided into two major categories: broad-spectrum antibiotics which are effective
against both Gram-positive and negative bacteria, and narrow-spectrum antibiotics, which are
only effective against Gram-positive bacteria. Based on this mechanism, Gram-negative bacteria
are more resistant to antibiotics. Second, bacteria can reduce the expression of porin proteins as a
way of reducing accessibility of antibiotics to their targets.99-100 Many relatively small and
hydrophilic antibiotics can diffuse through porins as a way of entering bacteria. Some bacteria
grow

resistance

by

downregulating

porin

proteins

expression.

For

example,

in

Enterobacteriaceae, this mechanism significantly contributes to resistance to relatively new
antibiotics such as carbapenem.99-100 The third mechanism of reducing accessibility of antibiotics
to their targets is the overexpression of efflux pumps.101-103 Many antibiotics can be effectively
transported out of the bacterial inner space by active efflux pumps and this is the major resistant
mechanism of MDR strains. Some of these efflux pumps have a relatively narrow substrate
spectrum, however, many can recognize a wide range of antibiotic with distinct structural

56

features.104-105 To make it even worse, some efflux pumps are encoded by plasmid DNA, which
means they have been mobilized on the plasmid and can be transferred among bacteria.88

Figure 2.2 Antibiotics resistance by inactivation of antibiotics
Even if some antibiotics are “lucky” enough and manage to get inside the inner space of
bacteria, bacteria have other ways to inactive these antibiotics (Figure 2.2).88, 106 First, bacteria
can change the target of antibiotics by mutations, leading to reduced affinity between the
antibiotics and their targets and inactivation of antibiotics (Figure 2.2, pathway 1). For example,
vancomycin inhibits bacterial cell wall synthesis in Gram-positive bacteria by binding to the two
D-ala residues on the end of the peptide chains and thus preventing the cross-linking of the
bacterial cell wall. In the vancomycin-resistant bacteria, the last D-ala residue is replaced by a Dlactate, which abolish the binding between vancomycin and its target.106-107 Erythromycin
inhibits bacteria growth by binding to rRNA and preventing protein synthesis. The erythromycin
ribosome methylase (erm) family of genes can methylate 16s rRNA and abolish the binding
affinity of erythromycin.106 The polymyxin antibiotics exert their effect by binding to LPS.
Recently, many drug-resistant Gram-negative strains have been shown to reduce the negative
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charge density of LPS and thus, reduce the binding affinity of polymyxin and LPS.108 Second,
bacteria have developed the ability to chemically modify antibiotics as a way of inactivating
antibiotics (Figure 2.2, pathway 2). Many enzymes have been identified to degrade or modify
antibiotics from different families such as β-lactams, phenicols, macrolides, and aminoglycosides.
β-Lactam antibiotics, from the first generation like penicillin to the latest carbapenems, can all be
hydrolyzed by a variety of β-lactamase and the plasmid-encoded β-lactamase gene can rapidly
spread.94, 106
2.1.2

Combinational therapy for treating MDR bacterial infections

Along with the emergence of MDR strains are the decreasing rates of new antibiotics
discovery. During 1983-1987, 16 new antibiotics were put into the market. This number dropped
to 10 during 1993-1997 and further down to 2 during 2008-2012. In response to the increasing
drug-resistant bacterial infections, new antibiotics development is needed more than ever.109
However, the development of new therapeutics is a long and arduous process, taking ~10 years
and involving the collaborative work of large teams in a pharmaceutical company covering areas
such as safety, metabolism, pharmacokinetics, formulation, stability, drug-drug interactions,
among many others, before clinical work can begin.110 In addition, the process is very costly with
the cost of developing a new chemical entity (NCE) being over $2.5B (2016) and the pre-clinical
portion being over $1B.111 Even with newly developed antibiotics, resistance to them by the
ever-evolving bacteria is expected, usually within a few years; and the over usage of antibiotics
further contributes to this worsening situations.109 Thus, sensitizing drug-resistant bacteria to
existing antibiotics with well-defined efficacy and side effect through combinational therapy is a
very attractive and reliable approach.89 Combination approach through the use of β-lactamase
inhibitors has gained some success in the past decades. However, their disadvantages have
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greatly limited their usage.112-113 For β-lactamase inhibitors, they mainly sensitize bacteria with
over-expressed β-lactamase and work exclusively with β-lactam class antibiotics. So, for other
drug-resistant mechanism and other classes of antibiotics, β-lactamase inhibitors have very
limited efficacy.112 Using efflux pumps inhibitors is also not a very practical strategy. Bacteria
express various families of efflux pumps with different structures, so it can be very difficult to
build efflux pump inhibitors to suppress all of them or even just some major ones, especially in
the case that different drug-resistant bacteria may overexpress different family of efflux
pumps.103, 114
To provide a more efficient solution, we took a step back and assessed the comprehensive
bacterial drug-resistant mechanisms. We recognized that drug-resistant problems are essentially
permeability problems and disruption of the outer membrane permeability can be a viable
approach .94,

106

As mentioned above, the first drug-resistant mechanism is the limitation of

accessibility of antibiotics towards their targets. In these cases, the antibiotics show reduced
activity simply just because that they can’t reach their target and the bacteria gained resistance to
a wide range of antibiotics through these this mechanism. Along with this line, the usage of
membrane disruptors to make the membrane “leaky” to accelerate the penetration and
accumulation of antibiotics can make drug-resistant bacteria susceptible again. The second
category of drug-resistant mechanisms is the inactivation of antibiotics, those drug-resistant
mechanisms would only lead to the resistance of one specific class of antibiotics, theoretically, a
simple switch to other antibiotics would solve the problem. It is true in many cases, however,
this inactivation mechanism is usually coupled with the first mechanism, which means the switch
to other antibiotics would also face the same permeability problem. For example, the usage of
hydrophobic, large antibiotics such as clarithromycin, novobiocin or rifampicin to treat
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carbapenem-resistant Gram-negative bacteria still would not work even though those bacteria
share the same protein targets with susceptible strains. However, we reasoned the usage of
bacterial membrane disruptors, to accelerate the penetration and accumulation of antibiotics
which are not considered active against Gram-negative bacteria previously, can overcome the
second category of resistant mechanism.
2.2

Results and discussion
2.2.1

In vitro activity test of bacterial sensitizers

Figure 2.3 Structures of bacterial sensitizers.

We focused on sensitizing Gram-negative bacteria because Gram-negative bacteria pose
a greater threat than Gram-positive bacteria. Although researchers haven’t fully revealed the
mechanism why the outer-membrane of Gram-negative bacteria is such an efficient barrier again
many antibiotics, researchers gradually realized that LPS, especially the lipid A component of
LPS plays an essential part in preventing the antibiotics’ penetration.115-117 So, lipid A could be
an attractive target to disrupt Gram-negative bacterial outer membrane. Polycation peptides are
known to bind to lipid A and thus disrupt Gram-negative bacterial outer membrane and
polymyxin antibiotics family are a typical example.118 At a high dosage, they can cause the
linkage of cytoplasmic components and bacterial death, while at a low concentration, they can
permeabilize the outer membrane and facilitate the uptake of hydrophobic antibiotics.119-120 Their
sensitization effect on various drug-resistant Gram-negative strains has been validated both in
vitro and in vivo.119, 121 However, Polycation peptides would unselectively binds to tissues and
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cause severe toxicity such as neurotoxicity and nephrotoxicity and have a relatively short halflife in serum, which greatly limits their application. Following this line, we wanted to design
bacteria sensitizers via binding to lipid A with a reduced toxicity, better pharmacokinetics.115
Some di-amidine compounds are known to binding to lipid A with great affinity.122-123
Pentamidine, an antimicrobial used to treat pneumocystis pneumonia, was recently found to
sensitize Gram-negative bacteria towards existing narrow-spectrum antibiotics such as
erythromycin, novobiocin by Dr. Eric Brown’s lab.116 Its effect on Gram-negative bacteria such
as polymyxin-resistant Acinetobacter baumannii was verified in an infection model on mice.
Inspired by all the above facts, we aimed to design and synthesize di-amidine compounds with
proper pharmaceutical property and use them to sensitize Gram-negative bacteria.
Various di-amidine compounds with different linkers and substitution patterns were
prepared by Dr. David Boykin’s lab. These compounds are screened and tested for their ability to
sensitize wild type E. coli, toward known antimicrobials. DB2560 (a compound from the Boykin
lab) was identified as one of the lead compounds (Figure 2.3). The MIC (Minimum inhibitory
concentration) of DB2560 on wild type E. coli was determined to be 120 µg/ml and 10 µg/ml
DB2560 was found to exhibit minimal bacterial growth inhibition (75% growth density
compared with the none-treatment group). However, 10 µg/ml DB2560 was able to lower the
MIC of erythromycin from 50 to 1.5 µg/ml (Figure 2.4a). Such results mean that 10 µg/ml
DB2560 can sensitize E. coli towards erythromycin by more than 32-folds. We used pentamidine
as a positive control.116 Pentamidine was only able to sensitize E. coli for less than 2-fold under
the same conditions. This means DB2560 is 10-times more potent than pentamidine. In the case
of rifampicin, the MIC against E. coli with and without 10 µg/ml DB2560 was 0.4 and 12.5
µg/ml, offering a 32-fold sensitization. To test whether DB2560 showed a synergistic or additive
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effect, we calculate the fractional inhibitory concentration (FIC) index (See Table 2.1 for
calculation equation). FIC index is used to describe the relationship of two drugs, if an FIC is
smaller than 0.5, these two drugs are considered to synergize with each other; while if FIC is
between 0.5 and 1, the two drugs have an additive effect with each other.124 The FIC index for
the combination of DB2560 with erythromycin and rifampicin was calculated to be 0.12,
demonstrating a synergistic effect between DB2560 and erythromycin or rifampicin.

Figure 2.4. Membrane disruptors sensitize wild type E. coli towards erythromycin
and rifampicin.
E. coli was cultured with antibiotics at various concentrations in the presence or absence
of bacterial sensitizer for 24 h at 37 °C. Then bacterial growth density was determined by
measuring OD600. ***: p <0.01.

As shown in Table 2.1, 10 µg/ml DB2560 can sensitize wild type E. coli towards a wide
range of antibiotic with distinct antimicrobial mechanisms such as novobiocin (8-fold),
clindamycin (16-fold), clarithromycin (16-fold), trovafloxacin (8-fold), polymyxin B (4-fold),
chloramphenicol (8-fold), and tetracycline (2-fold). Based on the data in Table 2.1, we can
conclude that DB2560 tend to sensitize E. coli more efficiently towards narrow-spectrum
antibiotics than broad-spectrum antibiotics. This is not surprising because the Gram-negative
outer membrane serves as an effective barrier against large, hydrophobic antibiotics. What’s
surprising is that DB2560 can also sensitize E. coli towards many broad-spectrum antibiotics
such as clindamycin, trovafloxacin, and chloramphenicol, with a FIC index of 0.15, 0.20 and
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0.20, respectively. These data remind us that the outer membrane of Gram-negative is such an
effective barrier even some small antibiotics are having trouble penetrating it.

Table 2.1 DB2560 sensitize wild type E. coli towards various antibiotics
Antibiotics (AB)

MIC
MIC of AB
Sensitiz
FIC
of AB alone with DB2560
ation fold
Erythromycin
50
1.5
32
0.11
Novobiocin
100
12.5
8
0.21
Rifampicin
12.5
0.4
32
0.11
Chloramphenicol
6
0.75
8
0.21
Clarithromycin
50
3
16
0.14
Tetracycline
1.6
0.8
2
0.75
Clindamycin
250
15
16
0.14
Trovafloxacin
0.025
0.003
8
0.21
Polymyxin B
1.6
0.4
4
0.33
Levofloxacin
0.05
0.012
4
0.33
DB2560 concentration: 10 µg/ml. Sensitization fold = MIC of antibiotics only /MIC of
antibiotics with Membrane disruptor; MIC of DB2560 is 120 µg/ml.
𝑀𝐼𝐶 𝑜𝑓 𝑎𝑛𝑡𝑖𝑏𝑖𝑜𝑡𝑖𝑐𝑠 𝑤𝑖𝑡ℎ 𝑀𝐷 𝑀𝐼𝐶 𝑜𝑓 𝑀𝐷 𝑖𝑛 𝑡ℎ𝑒 𝑝𝑟𝑒𝑠𝑒𝑛𝑐𝑒 𝑜𝑓 𝑎𝑛𝑡𝑖𝑏𝑖𝑜𝑡𝑖𝑐𝑠
𝐹𝐼𝐶 =
+
𝑀𝐼𝐶 𝑜𝑓 𝑎𝑛𝑡𝑖𝑏𝑖𝑜𝑡𝑖𝑐𝑠 𝑜𝑛𝑙𝑦
𝑀𝐼𝐶 𝑜𝑓 𝑀𝐷 𝑜𝑛𝑙𝑦
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2.2.2

Mechanism study of bacterial sensitizers

Figure 2.5. A schematic explanation of an HPLC study to detect the antibiotics
concentration inside E. coli.

We reasoned since DB2560 can sensitize E. coli to a variety of antibiotics with distinct
antimicrobial pathways, DB2560 should act through facilitating the uptake of antibiotics. The
antibiotic concentration inside E. coli with and without DB2560 was measured (Figure 2.5).
However, we could not use an active antibiotic to do so because of its bactericidal effect. The
inactivated form of antibiotic need to be used is that the active antibiotics would kill the bacteria
or inhibit bacterial growth, which would lead to results that cannot be compared against other
control experiments. A close analog of novobiocin – O-methyl novobiocin, an inactivated form
of novobiocin was used for this experiment. As described in Figure 2.5, E. coli was cultured with
50 μg/ml O-methyl novobiocin for 24 h at 37 °C with continuous shaking in the absence and
presence of 10 µg/ml DB2560. Then, E. coli was centrifuged, and the supernatant was removed.
To the precipitation, which contained E. coli, was added PBS; the resulting mixture was
sonicated to lyse the cell. The mixture was diluted with 3× acetonitrile and centrifuged. The
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supernatant, which contained O-methyl novobiocin, we then analyzed by HPLC. The O-methyl
novobiocin concentrations inside the bacteria increased 8.8-fold in E. coli in the presence of 10
µg/ml DB2560. Such results correlate well with the fact that 10 µg/ml DB2560 can sensitize E.
coli towards novobiocin for 8-fold. Another piece of evidence supporting this point is in the
failure for DB2560 to sensitize E. coli strain NR698 (Figure 2.7b), a “leaky” stain which has
greatly increased permeability to antibiotics compared to the wild type. Based on the above
evidence, we concluded that DB2560 sensitizes bacteria by facilitating the penetration of
antibiotics.

Figure 2.6 Structure of O-methyl novobiocin.

We then analyzed how DB2560 increase the uptake of antibiotics. As we discussed
above, DB2560 was designed to binding to lipid A. High concentrations of Mg2+ are known to
re-enforce the integrity of outer membrane by promoting electrostatic interactions between
adjacent lipid A molecules through binding to the di-phosphate groups.125 As shown in Figure
2.7c, when E. coli was cultured in the presence of 21 mM of Mg2+, DB2560 failed to sensitize E.
coli. We reasoned that DB2560 acted by binding to lipid A. Specifically, the di-amidine group
would bind to the di-phosphate group, the same site of Mg2+ binding. So, when a high
concentration of Mg2+ was introduced, it could conceptually compete against DB2560 for
binding with the target, lipid A. We also experimented by adding extra LPS, which contained
lipid A, to the culture media and found decreased ability for DB2560 to sensitize E. coli,

65

presumably because of the competition in binding between DB2560 and lipid A in the outer
membrane as compared to in solution (Figure 2.7c). Such results further support the idea that
DB2560 disrupts membrane integrity by binding to lipid A. We concluded that DB2560
sensitizes E. coli by disrupting bacterial membrane integrity through binding to lipid A in Gramnegative bacteria, leading to increased permeability of antibiotics.

Figure 2.7 Mechanism study of bacterial sensitizers.
HLPC peak of O-methyl novobiocin inside the E. coli (a, 10 µg/ml DB2560) in the presence
(Line 2) and absence (Line 1) of DB2560. Bacteria were cultured with 50 µg/ml O-methyl
novobiocin with or without DB2560 for 24 h at 37 °C, after which bacteria were centrifuged,
lysed and the O-methyl novobiocin inside bacteria was detected by HPLC at 280 nm. (b).
DB2560 fails to sensitize NR698, a membrane “leaky” E. coli strain. (c). 2 mg/ml LPS or 21 mM
Mg2+ can abolish the sensitization ability of DB2560 on wild type E. coli.
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2.2.3

Bacteria showed low resistance frequency towards bacterial sensitizers
Table 2.2 DB2560 can decrease the bacterial resistance frequency towards
antibiotics
Resistance frequency to DB2560
Resistance frequency
to DB2560
and antibiotics combination

Trovafloxacin

13/2×108

0/2×108

Chloramphenicol

1/2×108

0/2×108

Polymyxin B
2/2×108
0/2×108
For trovafloxacin, 4 times MIC was used; For Polymyxin B, 3 times MIC was used; For
chloramphenicol, 2 times MIC was used.

One major concern for antibiotic discovery/usage is that bacteria can develop resistance
quickly to antibiotics. However, in our case, we discovered bacteria showed low resistance
frequency towards the bacterial sensitizer. Briefly, E. coli was challenged with an antibiotic at a
concentration of 2 to 6-fold that of the MIC and 10 µg/ml DB2560 on agar plates. Colonies that
can survive these conditions are considered resistant mutant strains towards this combinational
therapy. We did identify drug-resistant strains towards combinational therapy. However, it was
found that all this resistance ended up being towards the antibiotics themselves, not the bacterial
sensitizers, as evidenced by the vulnerability of these mutant strains toward DB2560. For
example, when E. coli was challenged with trovafloxacin at a concentration of 4-times that of the
MIC and 10 μg/ml DB2560, 13 mutant colonies were observed. We then tested if 10 μg/ml
DB2560 can still sensitize these mutant strains towards another antibiotic, rifampicin. It turned
out that all these stains were still susceptible to the combination of DB2560 with rifampicin.
In total, 6*108 CFU E. coli was challenged with this combination therapy and 16 mutant
strains were identified to be resistant. Of all these 16 strains, none of them showed resistance to
DB2560. Thus, the resistance frequency towards 10 µg/ml DB2560 in the combination therapy
was < 1/6*108. The emergence of drug-resistance strains is essentially a selective process under
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high survival pressure caused by antibiotics. We reasoned at the dosage used, those bacterial
sensitizers have very limited inhibition and selective pressure on bacteria. As a result, bacteria
tend to develop resistance towards antibiotics instead of the bacterial sensitizers studied.
2.2.4

Bacterial sensitizers sensitize various MDR strains towards existing antibiotics

We haven’t got the comprehensive structure and activity relationship of these di-amidine
analogs, but we are able to make more potent bacterial sensitizers BW-MD-108 and BW-MD115 (Figure 2.3, Table 2.3).

10 μg/ml DB2560 was shown to sensitize E. coli towards

clarithromycin by 16-fold, while BW-MD-108 was able to achieve 32-fold sensitization at the
same concentration (Table 2.5). BW-MD-115 was even more potent than BW-108. At 5 μg/ml,
BW-MD-115 was able to sensitize E. coli towards clarithromycin by 32-fold, while BW-MD108 only achieved 8-fold sensitization at the same concentration.
Table 2.3 Potency comparison of lead compounds
Sensitization
E. coli
MDR K. pneumoniae
MDR S. Typhimurium
fold
DB2560a
16
>64
>64
DB2560b
4
N/A
8
a
MD-108
>32
>512
>512
MD-108b
8
>64
>128
b
MD-115
32
>256
>256
a: 10 µg/ml; b: 5 µg/ml; The sensitization fold was based on the combination with
clarithromycin. N/A: Not tested.
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The structure of lipid A is conservative among different Gram-negative bacterial species.
Therefore, we figured that DB2560 and its analogs would be able to sensitize a variety of Gramnegative bacteria. Drug-resistant bacteria, especially carbapenem-resistant Klebsiella and
Salmonella, have caused a great threat to public health and are listed as Priority 1 Pathogens by
the World Health Organization (WHO).126-128 Klebsiella species are opportunistic human
pathogens and can cause a variety of diseases including pneumonia, urinary tract infections, soft
tissue infections, and diarrhea.127 Salmonella have been reported to cause 1.2 million illnesses
each year in the US alone. It can induce diarrhea, fever, abdominal cramps, and food is the main
source of infection.128 We then tested MD-115 and MD-108 on MDR Klebsiella pneumoniae and
MDR S. typhimurium. These two MDR strains are known to be resistant to almost all major
broad-spectrum classes of antibiotics such as ampicillin (MIC > 160 µg/ml), kanamycin (MIC >
160 µg/ml), chloramphenicol (MIC > 40 µg/ml), tetracycline (MIC > 80 µg/ml), polymyxin

(MIC = 10 µg/ml), methicillin (MIC > 160 µg/ml), clindamycin (MIC > 160 µg/ml). For other

Figure 2.8 MD-115 sensitizes MDR K. pneumoniae towards rifampicin.
MDR K. pneumoniae was cultured with antibiotics at various concentrations in the presence
or absence of bacterial sensitizer for 24 h at 37 °C. Then bacterial growth density was
determined by measuring OD600. ***: p <0.01.
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narrow-spectrum antibiotics, which are naturally ineffective against K. pneumonia and S.
typhimurium, such as erythromycin, clarithromycin, rifampicin, and novobiocin, their MIC
values are more than 320 µg/ml.
As can be seen from Table 2.4 and Table 2.5, 10 µg/ml BW-MD-108 were able to
sensitize MDR K. pneumoniae and MDR S. typhimurium towards various antibiotics such as
narrow-spectrum antibiotics erythromycin (>32-fold) and novobiocin (>8-fold) as well as broadspectrum antibiotics tetracycline (2 to 4-fold) and clindamycin (>10-fold). Among them, the
combinations between BW-MD-108 with clarithromycin or rifampicin are the most promising
ones. 10 µg/ml BW-MD-108 were able to sensitize MDR K. pneumoniae strains towards
clarithromycin or rifampicin by more than 512 and 128-fold, respectively. 10 µg/ml BW-MD108 were able to sensitize MDR S. typhimurium strains towards clarithromycin or rifampicin by
more than 512 and 1000-fold, respectively. The MIC value of clarithromycin on MDR K.
pneumoniae and MDR S. typhimurium in the presence of 10 µg/ml BW-MD-108 was 0.63
μg/ml, which are clinically relevant concentrations. For clarithromycin, with a single dose of
1000 mg through a 60 min intravenous infusion, the peak concentration (Cmax) of the parent
drug in plasma can achieve 9.40 μg/ml,129 which is much higher than the MIC in vitro. The MIC
values of rifampicin on MDR K. pneumoniae and MDR S. typhimurium in the presence of 10
µg/ml BW-MD-108 were 2.5 and 0.31 µg/ml, which are also clinically relevant concentrations.
For rifampicin, with a single 600 mg dose through oral administration, peak serum concentration
of 10 μg/ml generally can be achieved.130-131 Considering the MIC of rifampicin when used with
10 µg/ml BW-MD-108, it is clear that the effect of the sensitizer can easily allow the use of
rifampicin to treat MDR K. pneumoniae and MDR S. typhimurium.
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We then tested BW-MD-115 with rifampicin, the most promising combination so far on
MDR K. pneumoniae and MDR S. typhimurium. In the presence of 10 µg/ml BW-MD-115, the
MIC of rifampicin on MDR. K. pneumoniae was 0.16 μg/ml, a 2000-fold sensitization (Figure
2.8). BW-MD-115 was also able to sensitize MDR S. typhimurium towards rifampicin. 5 µg/ml
BW-MD-115 was able to bring the MIC from more than 320 µg/ml to 0.16 µg/ml and achieve a
2000-fold sensitization.
Table 2.4 MD-108 sensitize MDR K. pneumoniae towards various antibiotics
Antibiotics (AB)

MIC of AB MIC of AB with MD- Sensitization
FIC
alone
108
fold
Erythromycin
>320
10
>32
<0.19
Novobiocin
>320
40
>8
<0.38
Clarithromycin
>320
0.63
>512
<0.14
Rifampicin
>320
2.5
>128
<0.13
Clindamycin
>160
10
>16
<0.19
Trimethoprim
>160
>160
No effect
N
Tetracycline
20
5
4
0.38
Methicillin
>320
>160
No effect
N
Kanamycin
>320
>160
No effect
N
BW-MD-108 concentration: 10 µg/ml. Sensitization fold = MIC of antibiotics only /MIC of
antibiotics with Membrane disruptor; MIC of BW-MD-108 is more than 80 µg/ml. N: not
calculated.

Form table 2.4 and 2.5, of course, the sensitizers described would not be expected to be
effective in overcoming resistant problems associated with over-expression of metabolizing
enzymes such as -lactamases against -lactams. In this case, these membrane disruptors won’t
work because even they facilitate the penetration of the antibiotics, the antibiotics would be
quickly metabolized by the bacteria. So, we figured in these cases, the reasonable way is to
switch to another antibiotic combination. One potential challenge in using this antimicrobial
combination therapy is that the sensitizers and the antibiotics may have different
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pharmacokinetics. This is true for any combination therapy. This potential issue can be addressed
by using a different class of antibiotics or different antibiotics under the same class to match the
pharmacokinetics of bacterial sensitizers. Alternatively, the structures of bacterial sensitizers can
be modified to match the pharmacokinetics of antibiotics used. Animal model work is needed to
understand the effect of pharmacokinetics and pharmacodynamics.

Table 2.5 MD-108 sensitize MDR S. typhimurium towards various antibiotics
Antibiotics (AB)

MIC of
alone
Erythromycin
>320
Novobiocin
>320
Clarithromycin >320
Rifampicin
>320
Clindamycin
>160
Trimethoprim
>160
Tetracycline
80<<160

AB MIC of AB with MD- Sensitization fold
108
5
>64
20
>16
0.63
>512
0.31
>1000
10
>16
>160
No effect
40
2 to 4

FIC

<0.16
<0.25
<0.14
<0.13
<0.19
N
0.620.38
Methicillin
>160
>160
No effect
N
Kanamycin
>160
>160
No effect
N
BW-MD-108 dosage: 10 µg/ml. Sensitization fold = MIC of antibiotics only /MIC of
antibiotics with Membrane disruptor (MD); MIC of MD-108 is more than 80 µg/ml. N: not
calculated.

In summary, we have developed a strategy to sensitize Gram-negative bacteria, especially
MDR strains, towards a wide range of existing antibiotics. This is achieved by the designing diamidine compounds that can bind to lipid A on the outer membrane of Gram-negative bacteria,
and thus disrupt the integrity of the outer membrane and facilitate the penetration of antibiotics.
MDR K. pneumoniae and MDR S. typhimurium, two WHO Priority 1 pathogens, were tested.
BW-MD-108 and BW-MD-115 were able to sensitize those two strains towards rifampicin and
clarithromycin to clinically relevant concentrations. More importantly, bacteria showed low
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resistance frequency towards the combination therapy and even lower resistance frequency
towards the bacterial sensitizers themselves.

2.3

Experimental section
2.3.1

Synthesis of bacterial sensitizers

All solvents were of reagent grade and were purchased from Fisher Scientific and
Aldrich. Reagents and were purchased from Aldrich, Oakwood, or VWR. The stationary phase
of chromatographic purification silica (230 × 400 mesh, Sorbtech). Silica gel TLC plate was
purchased from Sorbtech. 1H-NMR (400 MHz) and 13C-NMR (100 MHz) spectra were recorded
on a Bruker Avance 400 MHz NMR spectrometer. Mass spectral analyses were performed on an
ABI API 3200 (ESI-Triple Quadruple). HPLC was performed on a Shimadzu Prominence UFLC
(column: Waters C18 3.5 μM, 4.6×100 mm). UV-Vis absorption spectra were recorded on a
Shimadzu PharmaSpec UV-1700 UV-Visible spectrophotometer. Fluorescence spectra were
recorded on a Shimadzu RF-5301PC fluorometer. 96-Well plates were read and recorded on a
PerkinElmer 1420 multi-label counter.
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Scheme 2.1 General method for the synthesis of di-amidine compounds

General procedures for the preparation of dinitriles (Method A)
A mixture of 1,3-bis (bromomethyl)-benzene/substituted benzene (5 mmol), 4hydroxybenzonitrile or 4-hydroxy substituted benzonitrile (10 mmol) and anhydrous K2CO3
(2.07 g, 15 mmol) in 10 ml DMF was heated at 45 °C for 4 h. Then the reaction mixture was
diluted with ice water (70 ml) and stirred for 30 min. The white precipitate was filtered, washed
with water, and dried in air. Then the white solid was dissolved in a solvent (75 ml) (DCM,
methanol or THF), dried over anhydrous MgSO4. MgSO4 was then filtered and the supernatant
was concentrated with rotavapor to afford crude product. The crude product was then triturated
with hexane, filtered and dried in vacuum to yield white solid in 80-90% yield.
General procedures for diamidines as dihydrochloride salt (Method B)
To a cold and stirred suspension of di-nitrile (1 mmol) in 15 ml dry THF was added 6.0
ml (6 mmol) of LiN(TMS)2 (1M in THF). The reaction was stirred for 24 h at r.t. Then the
mixture was cooled and acidified carefully with saturated ethanolic-HCl to form a white solid.
The mixture was stirred for 2 h, after which all solvents were removed under vacuum to afford a
crude product. The crude product was then diluted with ether and the mixture was filtered to
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obtain a white solid. The white solid was then diluted with 10 ml ice water, basified with 2M
NaOH to afford a white precipitate. The white precipitate was then filtered, washed with water
and dried in air. The solid was suspended in anhydrous ethanol (15 ml) and 5 ml saturated
ethanolic HCl for 6 h. Then ethanol was distilled off and the product was triturated with dry ether
and filtered. The solid was dried in vacuum at 80 ºC for 12 h to yield (65-75%) diamidine
dihydrochloride as white solid.
Synthesis of DB 2560

Scheme 2.2 Synthesis of DB2560

Reaction of 1,3-bis (bromomethyl)-5-methylbenzene (8, 1.38 g, 5 mmol) and 4hydroxybenzonitrile (9, 1.19 g, 10 mmol) yielded 1, 3-bis (4-cyano-phenoxy methyl)-5-methylbenzene as white solid (10, 1.58 g, 90%), using method A; 1H NMR (DMSO-d6): 7.67 (d, 4H, J
= 8.8 Hz), 7.34 (s, 1H), 7.26 (s, 2H), 7.17 (d, 4H, J = 8.8 Hz), 5.18 (s, 4H), 2.34 (s, 3H);

13

C

NMR (DMSO-d6): 163.7, 138.1, 136.4, 134.2, 128.2, 124.3, 119.1, 115.8, 103.0, 69.5, 20.9: MS:
HRMS-ESI-POS.: calc. for C23H18N2O2Na m/z 377.1266 (M++1), found m/z 377.1269.
4,4'-(((5-methyl-1,3-phenylene)bis(methylene))bis(oxy))dibenzonitrile (10, 0.354 g, 1
mmol) was converted to DB2560 as brown solid following Method B (0.33g, 71%); mp. 269-71
°C; 1H NMR (DMSO-d6): 9.47 (s, 4H), 9.29 (s, 4H), 7.88 (d, 4H, J = 8.0 Hz), 7.65 (d, 4H, J =
8.0 Hz), 6.51 (s, 1H), 6.49 (s, 2H), 5.21 (s, 4H), 2.24 (s, 3H);

13

C NMR (DMSO-d6): 165.4,

159.0, 143.3, 139.9, 128.3, 127.6, 127.3, 108.2, 99.3, 68.2, 21.4; MS: HRMS-ESI-POS.: calc.
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for

C23H25N4O2

m/z

389.1972

(M++1),

found

m/z

389.1976;

analysis

calc.

for

C23H24N4O2.2HCl.0.25H2O: C, 59.21; H, 5.73; N, 12.02; Found: C,59.41; H,5.66; N, 11.55.

Scheme 2.3 Synthesis of BW-MD-108

To 3,5-dibromotoluene (11, 0.98 g, 3.9 mmol) was added 1:1 DMF-Et3N (6ml). To this
solution, 3 mole % Pd(PPh3)4 and 4-Ethynylbenzonitrile (12, 1 g, 7.8 mmol) were added and
stirred for 5 minutes. Then, 6 mol % sodium ascorbate solution, 1 mol % CuSO4 solution in
DMF were added to the reaction mixture and stirred for 4 h at 80˚C. The reaction mixture was
extracted with ethyl acetate followed by ammonium chloride and saturated brine. The combined
organic layer was dried over anhydrous Na2SO4 and then concentrated in vacuum. The product
was purified by column chromatography using 5:1 hexane: ethyl acetate system to afford a white
solid (13, 0.67 g, 50%). 1H NMR (CDCl3) 7.67 – 7.58 (m, 8H), 7.55 (s, 1H), 7.38 (s, 2H), 2.38 (s,
3H); 13C NMR (CDCl3) δ 138.91, 133.13, 132.26, 132.23, 128.05, 122.78, 118.60, 111.90, 92.88,
88.29, 21.21.
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To 10% Pd/C in methanol (30ml) under argon gas was added to 4,4'-((5-methyl-1,3phenylene)bis(ethyne-2,1-diyl))dibenzonitrile (13, 0.5g, 1.46mmol). The argon gas was
exchanged for H2 gas and the reaction mixture was stirred overnight. The reaction mixture was
quenched with 100 ml CH2Cl2 and filtered through Celite. The mixture was then washed by
water. The combined organic layer was dried over anhydrous Na2SO4 and then concentrated in
vacuum to give the product as a pale-yellow solid (14, 0.45 g, 87.6%). 1H NMR (CDCl3) 7.56 (d,
4H, J = 8.3 Hz), 7.24 (d, 4H, J = 8.2 Hz), 6.81 (s, 2H), 6.67 (s, 1H), 2.97 – 2.88 (m, 4H), 2.87 –
2.78 (m, 4H), 2.29 (s, 3H);

13

C NMR (CDCl3) 147.46, 140.96, 138.41, 132.29, 129.43, 127.31,

125.75, 119.21, 109.98, 38.14, 37.27, 21.46; MS: HRMS-ESI-POS.: calc. for C22H30N4 m/z
351.1856(M++1), found m/z 351.1846.
4,4'-((5-methyl-1,3-phenylene)bis(ethane-2,1-diyl))dibenzonitrile (15, 0.35 g, 1 mmol)
was converted to BW-MD-108 as white solid following Method B (0.32 g,70%). 1H NMR
(DMSO-d6) 9.34 (s, 4H), 9.12 (s, 4H), 7.78 (d,4H, J = 8.3 Hz), 7.48 (d, 4H, J = 8.3 Hz), 6.93 (s,
1H), 6.90 (s, 2H), 2.97 – 2.94(m, 4H), 2.85 – 2.81 (m, 4H), 2.24 (s, 3H); 13C NMR (DMSO-d6)
165.45, 148.43, 140.98, 137.30, 129.08, 128.16, 126.88, 125.63, 125.50, 36.85, 36.56, 21.07;
MS: HRMS-ESI-POS.: calc. for C22H30N4 m/z 193.1230 (M/2++2), found m/z 193.1222; analysis
calc. for C25H28N4.2HCl.1.8H2O; C, 61.29; H, 6.91; N, 11.43; Found: C, 61.61; H, 6.71; N,
14.36.

Synthesis of BW-MD-115
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Scheme 2.4 Synthesis of MD-115

5-tert-Butylisophthalic acid (15, 4 g, 18 mmol) in THF (100ml) was added dropwise
under ice-bath conditions into a solution of lithium aluminum hydride (1.5 g, 38 mmol) in THF
(100 ml). The reaction was stirred for 1 h at 0 °C. Then the reaction was heated at 60 °C for 24 h.
The reaction was monitored by TLC. On completion, the reaction mixture was cooled to 0 °C
and quenched with methanol and water. The quenched reaction was filtered through Celite and
washed with EtOAc (100 mL). The solvent was removed under reduced pressure and was
extracted with EtOAc (3  100 mL), dried over MgSO4 and concentrated to give the desired diol
(5-(tert-butyl)-1,3-phenylene)dimethanol (16, 3.2 g, 94%); 1H NMR (CDCl3): 7.32 (d, 2H, J=1.3
Hz), 7.19 (s, 1H), 4.69 (s, 4H), 1.33 (s, 6H); 13C NMR (CDCl3) 152.17, 141.05, 123.57, 123.06,
65.72, 34.92, 31.51; MS: HRMS-ESI-POS.: calc. for C12H17O m/z 177.1274 (M+- H2O), found
m/z 177.127.
PBr3 (2.5 mL, 26 mmol) was added dropwise to a solution of diol (5-(tert-butyl)-1,3phenylene) dimethanol (16, 2.3 g, 11.8 mmol) in DCM maintained at 0°C. The reaction mixture
was stirred at room temperature for 4 h and then quenched with ice water. The solution was

78

extracted with CH2Cl2 (3  100 mL), dried over MgSO4 and concentrated to give the required
dibromo compound as a white solid (17, 3.4 g, 90%); 1H NMR (CDCl3): 7.34 (d, J=1.4 Hz, 2H),
7.26 (s, 1H), 4.49 (s, 4H), 1.33 (s, 9H);

13

C NMR (CDCl3): 152.66, 138.12, 126.98, 126.39,

34.92, 33.59, 31.35.
Reaction of 1,3-bis(bromomethyl)-5-(tert-butyl)benzene (17, 1.5 g, 4.7 mmol) and 2fluoro-4-hydroxybenzonitrile (18, 1.3 g, 9.4 mmol) yielded 1, 3-bis (2-fluoro-4-cyano-phenoxy
methyl)- 5-(tert-butyl)benzene as white solid (19, 1.52 g, 75%) following Method A. 1H NMR
(DMSO-d6): 7.86 (dd, J=11.3, 1.9 Hz, 2H), 7.68 (d, J=8.5 Hz, 2H), 7.50 (s, 2H), 7.45 (t, J=8.6
Hz, 2H), 7.37 (s, 1H), 5.30 (s, 4H), 1.29 (s, 9H);

13

C NMR (DMSO-d6): 152.16 (d, JC-F = 243.2

Hz), 150.86 (d, JC-F = 2.8 Hz), 139.52, 135.94, 129.72 (d, JC-F = 4.0 Hz), 128.47, 123.58, 119.97
(d, JC-F = 21.4 Hz), 118.03 (d, JC-F = 2.3 Hz), 115.31 (d, JC-F = 2.2 Hz), 104.58 (d, JC-F = 8.2 Hz),
71.10, 2.52; MS: HRMS-ESI-POS.: calc. for C24H27FN4O4 m/z 455.1547 (M++Na), found m/z
455.1541
1, 3-bis (2-fluoro-4-cyano-phenoxy methyl)- 5-(tert-butyl)benzene (19, 0.35 g, 0.8 mmol)
was converted to BW-MD-115 as brown solid following Method B (0.30g, 70.1%); 1H NMR
(DMSO-d6): 9.49 (s, 4H), 9.26 (s, 4H), 7.90 (dd, J=12.1, 2.2 Hz, 2H), 7.80 dd, J= 8.7, 1.1 Hz,
2H), 7.56-7.43 (m, 4H), 7.39 (s, 1H), 5.31 (s, 4H), 1.28 (s, 9H);

13

C NMR (DMSO-d6): 163.97,

152.33, 150.85 (d, JC-F = 10.4 Hz), 150.78 (d, JC-F = 178.7 Hz), 136.03, 126.03 (d, JC-F = 3.0 Hz),
125.22, 123.92, 119.96 (d, JC-F = 7.2 Hz), 116.30(d, JC-F = 21.0 Hz), 115.33, 70.86, 34.64, 31.22;
MS: HRMS-ESI-POS.: calc. for C26H29N4O2F2 m/z 467.2272(M++1), found m/z 467.2271.
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2.3.2

In vitro bacterial growth inhibition test

E. coli, MDR S. typhimurium, and MDR K. pneumoniae were cultured in Miller’s broth.
Bacteria were cultured at 37 °C overnight to reach a density of OD600 of 0.8 to 1.0. This bacteria
stock was diluted 800 times to determine MIC.

Bacteria were incubated with various

concentration of antibiotics with or without the di-amidine compounds for 24 h at 37 °C with
continuous shaking of 200 rpm. The bacterial density was determined by OD600.
2.3.3

Bacterial resistance frequency test

E. coli was grown overnight in LB medium and concentrated to ∼1 × 109 c.f.u./ml in
fresh LB. Then A 100 μl volume of ∼1 × 109 c.f.u. /ml (equal to 108 c.f.u.) was then transferred
onto solid LB in 100 mm Petri dishes supplemented with antibiotics with or without 10 μg/ml
DB2560. The bacteria was incubated at 37 °C for 24 h. Then the colonies formed on the plate
were recorded and resistant frequency was calculated.
To determine if the colonies that can grow on the antibiotic and DB2560 combination
have developed resistance to DB2560 itself, these colonies were isolated and re-streaked into
LB medium containing the 10 μg/ml DB2560/rifampicin combination or rifampicin itself.
2.3.4

Experimental procedure for HPLC study

E. coli was cultured in Miller’s broth was cultured at 37 °C overnight to reach a density
of OD600 of 0.8 to 1.0. In one group, 150 μl E. coli stock, 300 μl 5 mg/ml O-CH3 novobiocin
and 300 μl DMSO was added to 30 ml fresh Miller’s broth as control; in the other group, 150 μl
E. coli stock, 300 μl 5 mg/ml O-CH3 novobiocin and 300 μl 1 mg/ml DB2560 in DMSO was
added to 30 ml fresh Miller’s broth. E. coli was incubated for 24 h at 37 °C with continuous
shaking of 200 rpm, after E. coli was centrifuged at 1500 rpm and re-suspended in PBS to reach
OD600 of 1.0. 1 ml bacteria in PBS was then lysis by sonication on ice for 15 min, followed by
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adding 2 ml MeOH, the mixture was then centrifuged at 2000 rpm for 5 min and the supernatant
was analyzed by HPLC. 20 μl of each sample was injected into Shimadzu Prominence UFLC
(column: Waters C18 3.5 μM, 4.6×100 mm, injection loop volume: 20μl). The mobile phase was
acetonitrile (ACN)/H2O (with 0.05% trifluoroacetic acid) with ratios defined as: 20%~55%
ACN, 0~10min; 55%~65% ACN, 10~20 min; 65%~20% ACN, 20~25 min;
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APPENDICES
Appendix A NMR Spectrum of RSS prodrugs

Appendix A.1 NMR Spectrum of perthiol species prodrugs
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Appendix A.2 NMR Spectrum of hydrogen persulfide prodrugs
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Appendix B NMR Spectrum of bacterial sensitizers
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